US20070190559A1 - Isolation of nucleic acid - Google Patents
Isolation of nucleic acid Download PDFInfo
- Publication number
- US20070190559A1 US20070190559A1 US11/671,426 US67142607A US2007190559A1 US 20070190559 A1 US20070190559 A1 US 20070190559A1 US 67142607 A US67142607 A US 67142607A US 2007190559 A1 US2007190559 A1 US 2007190559A1
- Authority
- US
- United States
- Prior art keywords
- dna
- sample
- cells
- genomic dna
- detergent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
- C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
- C12N15/1013—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by using magnetic beads
Definitions
- the present invention relates to the isolation of nucleic acid, and especially to the isolation of DNA or RNA from cells.
- the isolation of DNA or RNA is an important step in many biochemical and diagnostic procedures. For example, the separation of nucleic acids from the complex mixtures in which they are often found is frequently necessary before other studies and procedures e.g. detection, cloning, sequencing, amplification, hybridisation, cDNA synthesis etc. can be undertaken; the presence of large amounts of cellular or other contaminating material eg. proteins or carbohydrates, in such complex mixtures often impedes many of the reactions and techniques used in molecular biology. In addition, DNA may contaminate RNA preparations and vice versa. Thus, methods for the isolation of nucleic acids from complex mixtures such as cells, tissues etc. are demanded, not only from the preparative point of view, but also in the many methods in use today which rely on the identification of DNA or RNA eg. diagnosis of microbial infections, forensic science, tissue and blood typing, detection of genetic variations etc.
- RNA identifications it is important for a conclusive diagnosis to be certain that the detected sequence is derived from an RNA molecule and not from genomic DNA contamination in the sample. For this reason, methods for the separation of RNA from DNA are important. Also, for RNA isolation rapid methods are required since RNA molecules usually are very unstable and rapidly degraded by RNases present in cells and body fluids. The quality of the RNA is probably the most important factor in determining the quality of the final results in protocols utilising mRNA, especially for cDNA synthesis. It is important to avoid DNA contamination of RNA preparations for a number of reasons. Firstly, DNA increases viscosity making sample handling difficult leading to poor RNA yield and also RNA of poor quality with the likelihood of DNA contamination. Also, DNA contamination may trap RNase enzymes and make downstream applications such as RT-PCR worthless.
- RNA isolation involves lysis of the biological material by a detergent or chaotrope, possibly in the presence of protein degrading enzymes, followed by several extractions with organic solvents eg. phenol and/or chloroform, ethanol precipitation, centrifugations and dialysis of the nucleic acids.
- organic solvents eg. phenol and/or chloroform
- ethanol precipitation e.g. phenol and/or chloroform
- centrifugations e.g. phenol and/or chloroform
- dialysis of the nucleic acids e.g. phenol and/or chloroform
- the purification of RNA from DNA may involve a selective precipitation with LiCl or a selective isolation with acidic guanidinium thiocyanate combined with phenol extractions and ethanol precipitation.
- RNA purification strategies involve isolation of total RNA and fractionation of the isolated RNA. Preparation of high-quality mRNA is an important step in the analysis of gene structure and gene regulation.
- mRNAs have a poly(A)tail, typically about 50 to 300 nucleotides long. Such mRNA is referred to as polyadenylated or poly(A) + mRNA.
- polyadenylated or poly(A) + mRNA In separating this polyadenylated RNA from the non-adenylated RNA which accounts for 95% or more of a cell's total RNA, advantage is taken of this poly(A) tail and some type of affinity separation directed toward the poly(A) tail is performed.
- the conventional technology has involved purification of total RNA as a first step and selection of poly(A) + RNA by affinity chromatography using oligo(dT)-cellulose as the second step. This strategy, is rather time-consuming and labour-intensive.
- An alternative strategy for mRNA purification is to use oligo(dT) linked to solid supports such as microplates, latex, agarose or magnetic beads.
- RNA purification which may be used in conjunction with the solid phase approach is to carry out the lysis of the biological material and the subsequent hybridisation to oligo dT in LiCl and LiDS/SDS buffers, thereby avoiding extra steps such as phenol extraction or proteinase-K digestion.
- the whole direct mRNA isolation takes approximately 15 minutes and since the mRNA is stable for more than 30 minutes in the lysis buffer, this ensures the high quality of the mRNA purified.
- a disadvantage of this method is that mRNA per weight unit of tissue is affected by the amount of tissue used and above a critical threshold of lysed cells, the yield of mRNA decreases.
- GTC guanidinium isothiocyanate
- sarkosyl guanidinium isothiocyanate
- a GTC-buffer system is preferred by most researchers due to the ability of this chaotropic salt to inhibit RNases. This may also be used in combination with the magnetic bead approach.
- the viscosity of cell lysates in 4M GTC is high and the beads are not effectively attracted by the magnet, resulting in an increased risk for DNA contamination, both for beads and other solid phases, and lower yields.
- nucleic acid may be isolated from a sample in a form suitable for amplification or other downstream processes, by a simple and easy to perform procedure which involves treating the sample with detergent and allowing the nucleic acid to bind to a solid support, whereupon the nucleic acid may be readily separated from the sample, eg. by removal of the support.
- the binding of the nucleic acid is independent of its sequence.
- the present invention thus provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample.
- the nucleic acid may be DNA, RNA or any naturally occurring or synthetic modification thereof, and combinations thereof.
- the nucleic acid will be DNA, which may be genomic, or, cDNA, and single or double stranded or in any other form.
- the method of the invention may conveniently be coupled with a further step to isolate RNA from the same sample.
- RNA separations will be described in more detail below.
- the samples may be any material containing nucleic acid, including for example foods and allied products, clinical and environmental samples.
- the sample will generally be a biological sample, which may contain any viral or cellular material, including all prokaryotic or eukaryotic cells, viruses, bacteriophages, mycoplasmas, protoplasts and organelles.
- Such biological material may thus comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, protozoa etc.
- Representative samples thus include whole blood and blood-derived products such as plasma, serum and buffy coat, urine, feces, cerebrospinal fluid or any other body fluids, tissues, cell cultures, cell suspensions etc.
- the sample may also include relatively pure starting materials such as a PCR product, or semi-pure preparations obtained by other nucleic acid recovery processes.
- the nucleic acid-containing sample may, generally speaking, simply be contacted with the detergent, and a solid phase which may be added to the sample prior to, simultaneously with, or subsequently to the detergent. If necessary, this may be preceded by one or more separate steps to disrupt structural components such as cell walls or to achieve lysis. Procedures for achieving this are well known in the art. Thus, for example, although some cells eg. blood cells, may be lysed by the detergent alone, other cells, eg. plant or fungal cells or solid animal tissues may require more vigorous treatment such as, for example, grinding in liquid nitrogen, heating in the presence of detergent, alkaline lysis in the presence of detergent.
- lysis and melting of the paraffin
- certain more compact tissues may require enzyme treatment, for example using proteinase K to obtain sufficient release of nucleic acid.
- the various components are mixed and simply allowed to stand for a suitable interval of time to allow the nucleic acid to bind to the support.
- agents such as enzymes eg. proteinase K are being used, they may be included in with the detergent.
- the support is then removed from the solution by any convenient means, which will depend of course on the nature of the support, and includes all forms of withdrawing the support away from the sample supernatant, or vice versa, for example centrifugation, decanting, pipetting etc.
- the conditions during this process are not critical, and it has been found convenient, for example, simply to mix the sample with the detergent in the presence of a solid phase, and allow it to stand at room temperature, for 5 to 20 minutes, before separating.
- the reaction time is not critical and as little as 5 minutes is often enough. However, if convenient, longer periods may be used, eg. 0.5 to 3 hours, or even overnight.
- Mixing can be done by any convenient means, including for example simple agitation by stirring or vortexing. Also, if desired, higher or lower temperatures may be used, but are not necessary.
- the detergent may be any detergent, and a vast range are known and described in the literature.
- the detergent may be ionic, including anionic and cationic, non-ionic or zwitterionic.
- the term “ionic detergent” as used herein includes any detergent which is partly or wholly in ionic form when dissolved in water. Anionic detergents have been shown to work particularly well and are preferred. Suitable anionic detergents include for example sodium dodecyl sulphate (SDS) or other alkali metal alkylsulphate salts or similar detergents, sarkosyl, or combinations thereof.
- SDS sodium dodecyl sulphate
- other alkali metal alkylsulphate salts or similar detergents, sarkosyl, or combinations thereof.
- the detergent may be used in a concentration of 0.2 to 30% (w/v), eg. 0.5 to 30%, preferably 0.5 to 15%, more preferably 1 to 10%.
- concentrations of 1.0 to 5% eg. 0.5 to 5% have been shown to work well.
- the detergent may be supplied in simple aqueous solution, which may be alkaline or acidic, or more preferably in a buffer.
- Any suitable buffer may be used, including for example Tris, Bicine, Tricine, and phosphate buffers.
- a source of monovalent cations eg. a salt
- Suitable salts include chloride salts, e.g. sodium chloride, lithium chloride etc. at concentrations of 0.1 to 1M, eg. 250 to 500 mM.
- other components such as enzymes, may also be included.
- chelating agents eg. EDTA, EGTA and other polyamino carboxylic acids conveniently at concentrations of 1 to 50 mM etc.
- reducing agents such as dithiotreitol (DTT) or ⁇ -mercaptoethanol, at concentrations of for example 1 to 10 mM.
- Preferred detergent compositions may for example comprise:
- the detergent functions in the method to lyse the nucleic acid containing material, eg. the cells and nuclei to release the nucleic acid.
- the detergent is also believed to help to disrupt the binding of proteins, eg. DNA-binding proteins, to the nucleic acid and to reduce the problem of contaminants in the sample sticking to the solid support.
- the solid support may be any of the well known supports or matrices which are currently widely used or proposed for immobilisation, separation etc. These may take the form of particles, sheets, gels, filters, membranes, fibers, capillaries, or microtitre strips, tubes, plates or wells etc.
- the support may be made of glass, silica, latex or a polymeric material. Preferred are materials presenting a high surface area for binding of the nucleic acid. Although not wishing to be bound by theoretical considerations, it is believed that the nucleic acid binding process may be assisted by the nucleic acid “wrapping around” the support.
- Such supports will generally have an irregular surface and may be for example be porous or particulate eg. particles, fibres, webs, sinters or sieves. Particulate materials eg. beads are generally preferred due to their greater binding capacity, particularly polymeric beads.
- a particulate solid support used according to the invention will comprise spherical beads.
- the size of the beads is not critical, but they may for example be of the order of diameter of at least 1 and preferably at least 2 ⁇ m, and have a maximum diameter of preferably not more than 10 and more preferably not more than 6 ⁇ m. For example, beads of diameter 2.8 ⁇ m and 4.5 ⁇ m have been shown to work well.
- Monodisperse particles that is those which are substantially uniform in size (eg. size having a diameter standard deviation of less than 5%) have the advantage that they provide very uniform reproducibility of reaction.
- Monodisperse polymer particles produced by the technique described in U.S. Pat. No. 4,336,173 are especially suitable.
- Non-magnetic polymer beads suitable for use in the method of the invention are available from Dyno Particles AS (Lillestrom, Norway) as well as from Qiagen, Pharmacia and Serotec.
- magnetic beads are preferred.
- the term “magnetic” as used herein means that the support is capable of having a magnetic moment imparted to it when placed in a magnetic field, and thus is displaceable under the action of that field.
- a support comprising magnetic particles may readily be removed by magnetic aggregation, which provides a quick, simple and efficient way of separating the particles following the nucleic acid binding step, and is a far less rigorous method than traditional techniques such as centrifugation which generate shear forces which may degrade nucleic acids.
- the magnetic particles with nucleic acid attached may be removed onto a suitable surface by application of a magnetic field eg. using a permanent magnet. It is usually sufficient to apply a magnet to the side of the vessel containing the sample mixture to aggregate the particles to the wall of the vessel and to pour away the remainder of the sample.
- superparamagnetic particles for example those described by Sintef in EP-A-106873, as magnetic aggregation and clumping of the particles during reaction can be avoided, thus ensuring uniform and nucleic acid extraction.
- the well-known magnetic particles sold by Dynal AS (Oslo, Norway) as DYNABEADS, are particularly suited to use in the present invention.
- Functionalised coated particles for use in the present invention may be prepared by modification of the beads according to U.S. Pat. Nos. 4,336,173, 4,459,378 and 4,654,267.
- beads, or other supports may be prepared having different types of functionalised surface, for example positively charged or hydrophobic. Weakly and strongly positively charged surfaces, weakly negatively charged neutral surfaces and hydrophobic surfaces eg. polyurethane-coated have been shown to work well.
- solid supports which have been modified to permit the selective capture of desired cells, viruses etc. containing the nucleic acid.
- supports carrying antibodies, or other binding proteins, specific for a desired cell type may be used. This may introduce a degree of selectivity to the isolation of the nucleic acid, since only nucleic acid from a desired target source within a complex mixture may be separated.
- a support may be used to separate and remove the desired cell type etc. from the sample, following which, the detergent is added to achieve lysis, release of the nucleic acid, and binding to the support.
- the support may be provided with binding partners to assist in the selective capture of nucleic acids.
- binding partners for example, complementary DNA or RNA sequences, or DNA binding proteins may be used, or viral proteins binding to viral nucleic acid.
- the attachment of such proteins to the solid support may be achieved using techniques well known in the art.
- washing buffers or other media may be used. Generally speaking, low to moderate ionic strength buffers are preferred eg. 10 mM Tris-HCl at pH 8.0/10 mM NaCl. Other standard washing media, eg. containing alcohols, may also be used, if desired.
- the support carrying the nucleic acid may be transferred eg. resuspended or immersed into any suitable medium eg. water or low ionic strength buffer. Depending on the support and the nature of any subsequent processing desired, it may or may not be desirable to release the nucleic acid from the support.
- a particulate solid support such as magnetic or non-magnetic beads
- this may in many cases be used directly, for example in PCR or other amplifications, without eluting the nucleic acid from the support.
- elution is not necessary since although the DNA may be randomly in contact with the bead surface and bound at a number of points by hydrogen bonding or ionic or other forces, there will generally be sufficient lengths of DNA available for hybridisation to oligonucleotides and for amplification.
- elution of the nucleic acid may readily be achieved using known means, for example by heating, eg. to 65° C. for 5 to 10 minutes, and following which the support may be removed from the medium leaving the nucleic acid in solution. Such heating is automatically obtained in PCR by the DNA denaturation step preceding the cycling program.
- RNA from DNA may be removed by destroying the RNA before the DNA separation step, for example by addition of an RNase or an alkali such as NaOH.
- the method of the invention may be used to separate sequentially DNA and RNA from the sample. It may also be used to remove DNA from a sample in an RNA purification procedure.
- the sequential separation may take place using two different solid phases, for example solid supports which can differentiate between DNA and RNA.
- a method may comprise carrying out a first step separation to isolate DNA as described above.
- a further solid support can then be added to the sample to capture the RNA remaining in the sample, either by using a solid support that can bind the RNA or any remaining nucleic acid, or a solid support that can capture specific RNA molecules (eg. by carrying a complementary nucleic acid probe), or a subset of RNA molecules eg. polyadenylated RNA.
- RNA molecules eg. polyadenylated RNA.
- DNA isolation procedure of the invention may also readily be combined, as a preliminary step, with other conventional RNA purification procedures, for example DNA isolation with detergent according to invention may be carried out before a selective RNA precipitation step, for example using LiCl or before RNA separation using GTC and sarkosyl.
- the sample is lysed in the presence of detergent and the DNA is allowed to bind to a solid support, whereupon the DNA may readily be separated from the sample by removal of the support. If desired, the DNA can rapidly and easily be further handled for amplification or other downstream processes.
- the RNA may then be isolated. This can be by a solid phase based system as described above, including a repetition of the method of the invention, or by conventional techniques such as extractions, precipitations or affinity chromatography.
- a particularly advantageous embodiment of the invention is to use the isolation method of the invention to remove DNA from a sample prior to isolation of RNA, such that the viscosity of the lysed sample is reduced and a specific isolation of RNA molecules is favored which again reduces or avoids the possibility for DNA contamination of the RNA.
- Such a method also has the advantage of being quick to perform.
- the invention is advantageously amenable to automation, particularly if particles, and especially, magnetic particles are used as the support.
- kits represent a further aspect of the invention.
- this aspect of the invention provides a kit for isolating nucleic acid from a sample comprising a solid support and one or more detergents.
- kits may be buffers, salts, lysis agents eg. proteinases, chelating agents and reducing agents.
- lysis agents eg. proteinases, chelating agents and reducing agents.
- kits may further comprise means for isolating RNA eg. a second solid support for isolating RNA, for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.
- a second solid support for isolating RNA for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.
- FIG. 1 shows as optical density scan of DNA isolated as described in Example 1 (ordinate shows absorbance (OD), abscissa shows wavelength (nM)). Maximum absorbance (0.427) at 257.6 nM; minimum absorbance (0.292) at 236.4 nM; at a threshold of 0.100;
- FIG. 2 shows gel electrophoresis of a sample of DNA isolated as described in Example 1 (lane 1: isolation; lane 2: .lamda. Hind III (molecular weight marker));
- FIG. 3 shows agarose gel electrophoresis of the PCR product of Example 2 (lane 1: PCR product; lane 2: .lamda. Hind III; lane 3: negative PCR control); and
- FIG. 4 shows agarose gel electrophoresis of the PCR product of Example 5 (lane 1: .lamda. Hind III; lanes 2 and 3: isolations A and B respectively; lanes 4 and 5: negative control; lane 6: .lamda. Hind III).
- FIG. 5 show the comparison between traditionally isolated DNA and DNA isolated with Dynabeads DNA DIRECT.
- Panel I shows the amount of genomic DNA isolated from 10 ⁇ l of whole blood with Dynabeads DNA DIRECT including the optional elution step (lanes 1 and 2), with Dynabeads DNA DIRECT with the elution step omitted (lanes 3 and 4), and with traditional DNA isolation (lanes 5 and 6).
- the molecular weight marker in lane 7 is .lamda. HindIII.
- Panel II shows the integrity of DNA isolated by Dynabeads DNA DIRECT.
- Lanes 1 and 2 show AMXY PCR from 20 ng of DNA isolated with Dynabeads DNA DIRECT from a male and female donor respectively.
- Lanes 4 and 5 show AMXY PCR from 200 ng DNA isolated by traditional methods from a female and a male donor respectively.
- Lane 3 is the negative control.
- FIG. 6 shows the reproducibility of Dynabeads DNA DIRECT.
- the figure shows five independent Dynabeads DNA DIRECT isolations from each of two donors. Half of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
- Molecular weight markers are .lamda. HindIII (lanes marked M) or 100 bp ladder (lane marked L).
- FIG. 7 shows the effect of different anticoagulants.
- the figure shows Dynabeads DNA DIRECT isolations from whole blood that is not anticoagulated and from blood anticoagulated with EDTA, citrate, or S heparin. The two isolations from blood with the same anticoagulant were performed on blood from different donors (A or B). One quarter of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, except for heparin, where half the DNA obtained from 5 ⁇ l is shown. 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure, except for heparin, where 20% of the isolated DNA was used as starting material.
- FIG. 8 shows the effect of sample storage conditions.
- Panel I shows Dynabeads DNA DIRECT isolations from EDTA blood that has been used fresh, refrigerated for 4 days, or frozen for 4 days. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
- Panel II shows Dynabeads DNA DIRECT isolations from citrate blood that has been used fresh or air dried and rehydrated. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 ⁇ l of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
- FIG. 9 shows Dynabeads DNA DIRECT from bone marrow and culture cells.
- Panel I shows Dynabeads DNA DIRECT isolations from 1, 2 and 5 ⁇ l of bone marrow from each of two donors. A or B above the lanes denote the identity of the donor. Half of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure.
- Panel II shows two Dynabeads DNA DIRECT isolations from 4 ⁇ 10 5 Daudi cells. One tenth of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 1 ⁇ l of a total of 120 ⁇ l isolated DNA is shown in the lower part of the figure.
- the molecular weight marker is .lamda. HindIII for the genomic DNA and 100 bp ladder for the PCR products.
- FIG. 10 shows Dynabeads DNA DIRECT from formalin fixed, paraffin embedded material.
- Lane A is 20% of the PCR product from a reaction started with DNA isolated by DNA DIRECT from a formalin fixed, paraffin embedded section of liver.
- Lane M is molecular weight marker (100 bp ladder)
- lane B is positive control (PCR from 20 ng human DNA)
- lane C is negative control (PCR from water).
- FIG. 11 shows Dynabeads DNA DIRECT for mRNA purification.
- mRNA was isolated from 1 million Daudi cells per sample with Dynabeads Oligo(dT) 25 after removal of DNA with Dynabeads DNA DIRECT.
- Increasing amounts of DNA DIRECT Dynabeads were used to remove genomic DNA; 1 mg in lane 1 and 2; 2 mg in lane 3 and 4; 5 mg in lane 5 and 6 and 10 mg in lane 7 and 8.
- Lane 9 and 10 are controls where no DNA was removed before direct mRNA purification.
- the extra bands on the top of the picture show contaminating genomic DNA in lane 9 and 10.
- the two strong bands in all lanes represent ribosomal RNA.
- FIG. 12 shows the results of DNA isolation and PCR amplification from (A) bacteria, (B) fungi, (C) algae and (D) plants.
- DNA was isolated with 200 ⁇ l DNA DIRECT (one sample test) and 20% of the isolated DNA and 10% of the PCR products were analysed by agarose electrophoresis.
- DNA 2.5% of the isolated DNA was used per PCR reaction, for the other samples 5% was used.
- 16S rRNA regions were amplified from bacterial genomic DNA and from algae chloroplast DNA. From fungi- and algae genomic DNA, 18S rDNA were amplified. Amplification of the group I intron chloroplast trnL and parts of the genomic B15C gene are shown for plants.
- the negative controls are PCR on samples without DNA prepared in the same way as the other reactions.
- the solid phase was then washed twice with 1 ml washing buffer [50 mM NaCl/10 mM TrisCl pH 8.0/1 mM EDTA]. Finally, the beads, with bound DNA, were resuspended in 0.1 ml water, and incubated for 5 minutes at 65° C. The beads were attracted to a magnet, and the liquid phase withdrawn. The liquid phase was then analyzed for its DNA content. Results from an optical density scan ( FIG. 1 ) are in accordance with pure DNA. The OD 260 /OD 280 ratio is 1.72; pure DNA in water or TE has a ratio of 1.7-1.9. With pure DNA, the concentration can be determined from the OD 260 of the solution.
- Example 1 was repeated using the following combination of lysis buffers and washing buffers, and the following results were obtained: Lysis buffer Washing buffer Result 2% SDS 50 mM NaCl/1 ⁇ TE +++ 2% SDS/1 ⁇ TE 50 mM NaCl/1 ⁇ TE +++ 2% SDS/1 ⁇ TE/10 mM NaCl 50 mM NaCl/1 ⁇ TE +++ 5% SDS 50 mM NaCl/1 ⁇ TE +++ 5% SDS/1 ⁇ TE 50 mM NaCl/1 ⁇ TE +++ 5% SDS/1 ⁇ TE/10 mM NaCl 50 mM NaCl/1 ⁇ TE +++ 1% LiDS/10 ⁇ TE/0.5 M LiCl 50 mM NaCl/1 ⁇ TE +++ 1% LiDS/10 ⁇ TE/0.5 M LiCl 150 mM LiCl/1 ⁇ TE +++ 5% LiDS 150 mM LiCl/1 ⁇ TE +++ 5%
- This experiment consisted of two identical isolations. 50 ⁇ l blood was mixed with 50 ⁇ l PBS [150 mM NaCl/10 mM NaH 2 PO 4 /Na 2 HPO 4 , pH 7.4] and 10 ⁇ l (4 ⁇ 10 6 beads) Dynabeads® M-450 Pan-T (CD2) (available from Dynal AS, Oslo, Norway). The mixture was then incubated for 30 minutes at room temperature with gentle tilting and rotation. The cell/beads complex was attracted to a magnet and the fluid withdrawn.
- PBS 150 mM NaCl/10 mM NaH 2 PO 4 /Na 2 HPO 4 , pH 7.4
- Dynabeads® M-450 Pan-T CD2
- the cell/beads complex was then washed four times in 200 ⁇ l PBS, before 200 g Dynabeads® M-280* (as above) and 2001 lysis buffer [100 mM Tris-HCl, pH 8.0/500 mM LiCl/10 mM EDTA, pH 8.01/1% LiDS] was added. The mixture was incubated for 5 minutes at room temperature, before the DNA/beads complex was attracted to a magnet, and the supernatant withdrawn.
- the DNA/beads complex washed twice with 200 ⁇ l washing buffer [10 mM Tris-Hcl, pH 8.0/150 mM LiCl/1 mM EDTA, pH 8.0] and resuspended in 50 ⁇ l water. After 5 minutes at 65° C., the beads were attracted to a magnet and the supernatant transferred to a new tube. 5 ⁇ l of the supernatant was used as template for polymerase chain reaction (GAPDH PCR as described in Example 7), which gave large amounts of product, as visualised on agarose gel electrophoresis ( FIG. 4 ).
- GPDH PCR polymerase chain reaction
- genomic DNA was isolated from 5 ml of EDTA anticoagulated blood.
- Four isolations from 10 ⁇ l of the same blood sample were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway, containing beads equivalent to Dynabeads® M-280* as described in Example 1).
- the DNA from two of the isolations was eluted for 5 minutes at 65° C., while the DNA from the other two isolations was left in the presence of the Dynabeads. All the DNA from the four Dynabeads DNA DIRECT isolations was loaded onto an agarose gel, as was 0.2% of traditionally isolated DNA. The fraction of the traditionally isolated DNA loaded corresponds to the yield from 10 ⁇ l of blood (0.2% of 5 ml).
- Dynabeads DNA DIRECT lysis of the blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with 10 ⁇ l of blood in a 1.5 ml microcentrifuge tube (200 ⁇ g uncoated Dynabeads in Lysis/binding buffer). Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- MPC-E Dynamic's Magnetic Particle Collector E
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 ⁇ l of TE pH 8.0 (provided in the kit).
- the DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 ⁇ TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- DNA DIRECT was used to isolate DNA from ACD blood from two different donors, one male and one female. From each of the isolations, 10% was used as starting material for PCR amplification of an amplicon in the X-Y homologous amelogenin (AMXY) gene (Akane, A., K, Matsubara, H. Nakamura, S. Takahashi and K. Kimura. 1994. Purification of Highly Degraded DNA by Gel Filtration for PCR. BioTechniques 16 (2):235-238), as was 200 ng from each of two traditional DNA isolations.
- AXY homologous amelogenin
- PCR reactions were performed in a 50 ⁇ l reaction volume, 10 ⁇ PCR buffer (Perkin Elmer) was added to a final concentration of 1 ⁇ , dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers AMXY-1F (5′-CTGATGGTTGGCCTCAAGCCT-GTG-3′) and AMXY-4R (5′-TTCATTGTAAGAGCAAAGCAAACA-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the AMXY amplicon were 4 min at 94° C., 38 ⁇ [30 sec at 94° C., 30 sec at 55° C., 1 min at 72° C.], 10 min at 72° C.
- Lysis/binding buffer 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA
- sample A 3.6 ⁇ 10 6 cells/ml
- sample B 2.6 ⁇ 10 6 cells/ml
- Lysis of the blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- MPC-E Dynamic's Magnetic Particle Collector E
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit). This resuspension was used for PCR and gel electrophoresis without any elution.
- PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene was performed in a 50 ⁇ l reaction volume, 10 ⁇ PCR buffer (Perkin Elmer) was added to a final concentration of 1 ⁇ , dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers GAPDH-Forward (5′-ACAGTCCATGCCATCACTGCC-3′) and GAPDH-Reverse (5′-GCCTGCTTCACCACCCTTG-3′) were added per reaction.
- GAPDH-Forward 5′-ACAGTCCATGCCATCACTGCC-3′
- GAPDH-Reverse 5′-GCCTGCTTCACCACCCTTG-3′
- PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94° C., 34 ⁇ [30 sec at 94° C., 30 sec at 61° C., 1 min at 72° C.], 10 min at 72° C.
- Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from untreated whole blood as well as blood anticoagulated with EDTA, Citrate or Heparin. From each type of starting material, two separate isolations were performed, with blood from different donors.
- the buffer components in the kit are as described in example 6.
- Lysis of the DNA containing cells from blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with 5 ⁇ l Heparin blood or 10 ⁇ l of other blood samples in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- MPC-E Dynamic's Magnetic Particle Collector E
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 20-40 ⁇ l of TE pH 8.0 (provided in the kit). We used 40 ⁇ l as the standard volume, but 20 ⁇ l if the starting material was Heparin blood.
- PCR was performed directly on the suspension in TE, with the Dynabeads present. All PCR reactions were performed in a 50 ⁇ l reaction volume, 10 ⁇ PCR buffer (Perkin Elmer) was added to a final concentration of 1 ⁇ , dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction.
- Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from EDTA blood from two different donors: What was remaining of the blood samples were then divided into two, one part that was stored at +4° C. and one that was stored at ⁇ 20° C. After 4 days, the frozen samples were thawed, and DNA was isolated from both the frozen samples and the samples that had been kept at +4° C.
- the buffer components of the kit are as described in example 6.
- Lysis of the blood was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- MPC-E Dynamic's Magnetic Particle Collector E
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
- heparinized bone marrow 1, 2, and 5 ⁇ l of heparinized bone marrow from each of two healthy donors were used as starting material for DNA isolation with DNA DIRECT.
- the buffer components are as described in example 6. Lysis of the bone marrow was obtained by mixing 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT with 1-5 ⁇ l of heparinized bone marrow in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E(MPC-E)), and the lysate was aspirated and discarded.
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
- DNA isolation from 4 ⁇ 10 5 cultured cells was performed as described above, except that 1 ml (five sample tests) of Dynabeads DNA DIRECT was used. Accordingly, the washing steps were performed in 1 ml washing buffer.
- the DNA/Dynabeads complex was resuspended in 120 ⁇ l TE, and as for bone marrow, no elution step was performed after the resuspension.
- Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from a formalin fixed, paraffin embedded section of liver.
- the buffer components of the kit and the bead concentration are as described in example 6.
- Lysis of the sample was obtained by adding 200 ⁇ l (one sample test) of Dynabeads DNA DIRECT to the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads. The lysate, containing DNA and Dynabeads was transferred to a fresh tube, leaving cell debris and paraffin behind.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- MPC-E Dynamic's Magnetic Particle Collector E
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 ⁇ l of sterile water. This suspension, with the Dynabeads present, was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8.
- the PCR product was visualised on an ethidium bromide stained 1.5% agarose gel. 10 ⁇ l of the 50 ⁇ l reaction was loaded on the gel. Electrophoresis was performed in 1 ⁇ TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The result of this experiment is shown in FIG. 10 .
- PCR amplifiable material has clearly been obtained from the formalin fixed, paraffin embedded section of liver.
- mRNA was isolated from 1 million Daudi cells per sample. The cells were lysed in 0.75 ml Lysis/binding buffer with DNA DIRECT Dynabeads present in the buffer. The samples were incubated for 5 minutes and the DNA-Dynabead complexes were collected by applying a Dynal MPC-E magnet for 2 minutes. Different amounts of DNA DIRECT beads were used to remove genomic DNA; 1, 2, 5 and 10 mg per sample ( FIG. 11 ).
- the lysate from each sample was transferred to new tubes with 1 mg Dynabeads Oligo(dT) 25 according to standard procedure (Dynals mRNA DIRECT kit protocol).
- the Dynabeads were mixed with the lysate to capture the polyadenylated mRNA by hybridisation for 5 minutes at room temperature.
- the mRNA-Dynabead complexes were collected with the MPC-E magnet by placing the tubes in the magnetic stand for 2 minutes. The solution was removed and discarded. Washing solution with LiDS (0.75 ml) was added and the beads were washed thoroughly by pipetting up and down.
- the mRNA-Dynabead complexes were collected with the magnet, and the washing procedure was repeated once with washing buffer with LiDS and twice with washing buffer without detergent. Finally, the purified mRNA was eluted from the Dynabeads in 20 ⁇ l 5 mM Tris-HCl pH 7.5 buffer, by incubation at 65° C. for 2 minutes. The eluates were analysed by non-denaturing gel electrophoresis in a 1.0 t agarose gel with ethidium bromide. FIG. 11 shows the results from this experiment.
- Lysis/binding buffer 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer with LiDS: 0.15 M LiCl 0.1% LiDS 10 mM Tris-HCl pH 8.0 1 mM EDTA Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA
- E. coli and Baceillus cereus were grown overnight at 37° C. in LB medium, Agrobacterium tumefaciens was grown overnight in YEB medium for about 40 hours at 28° C. (Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbour Laboratory, NY.). Cyanobacteria and Prochlorthrix were grown in NIVA medium for 14 days at 18° C. using an illumination of 20 micro Einstein (Norwegian Institute of Water Research, 1991, Culture collection of algae). 20-200 million bacteria or 450,000 cyanobacteria were used per DNA isolation.
- Agar plates containing 2% malt extract was used for mycelia growth and incubated for 14 days at room temperature. Mycelia was isolated by scraping the surface of the agar plates with a spatula. Fungi fruitbodies were obtained from natural populations. In the range of 1-3 mg air dried and 3-20 mg fresh fungi fruitbodies were used per DNA isolation.
- Bakers yeast Saccharomyces cerevisiae was obtained from a commercial supplier. Algae were cultured under illumination in IMR-medium for 7 days (Eppley, R et al., 1967, Exp. Mar. Biol. Ecol. 1, 191-208). Fresh leaves from Arabidopsis thaliana and barley ( Hordeum vulgare ) were picked from young plants (3 weeks old). Epithelia were obtained from perch ( Perca fluvatilis ) fins. About 1 mg wet weight yeast, 30-100 mg young plant leaves and 100-400 mg perch were used per DNA isolation.
- Multicellular tissues with rigid cell walls were mechanically broken to increase DNA yield.
- Fungi fruitbodies were ground with forceps for about 2 minutes.
- Plant leaves were homogenised for 2 minutes in liquid nitrogen with a pestle (Kontes Scientific Instruments, Vineland, N.J., USA). For all other samples no mechanical work was required for cell breakage.
- DNA isolations were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway). Lysis of the cells and organisms were obtained by mixing 200 ⁇ l of Dynabeads DNA DIRECT (200 ⁇ g uncoated Dynabeads in Lysis/binding buffer) with the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 to 15 minutes to allow adsorption of genomic DNA to the Dynabeads. For some bacteria and for plants, incubation at 65° C. for 15 minutes was used to improve lysis before the adsorption step.
- Dynabeads DNA DIRECT kit, commercially available from Dynal AS, Oslo, Norway.
- the DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- MPC-E Dynamic's Magnetic Particle Collector E
- the complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 ⁇ l of TE pH 8.0 (provided in the kit) by vigorous pipetting. Elution was performed by heating the suspension to 65° C. for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.
- Lysis/binding buffer 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mm EDTA
- the amplicon was a 16S rRNA region corresponding to E. coli base 334 to 939 according to IUD numbering from bacteria and algae chloroplasts (Brosius, J., et al., 1978, Proc. Natl. Acad. Sci., USA, 57, 4801-4805).
- Primer CC has a 5′ end complementary to ⁇ 21 M13 universal primer, making it suitable for direct DNA sequencing. Amplification: 30 cycles of 96° C. for 15 seconds and 70° C. for 2 minutes.
- a 18S rRNA region (ca. 600 bp.) was amplified with the primers NS3 and NS4 as described by White et al., 1990. In “PCR Products, a Guide to Methods and Applications” by Innis, M. A. et al., page 315-322, Academic Press, New York.
- tRNL group I intron in chloroplasts were amplified with the primers C and D described by Fangan et al., 1994, BioTechniques 16, 484-494.
- a part of the Arabidopsis thaliana gene BI5C (800 bp) was amplified with the primers: 5′-CGGGATCCCTAGGAGACACGGCCG-3′ and 5′-GGAATTCGATCGGCGGTCTTGAAAC-3′
- Barley gene Bl5C (800 bp) was amplified with the primers 5′- 5′-CGGATCCCGTCATCCTCTTCTCGCACCCC-3′ and 5′-GGAATTCCCTTCTTGGAGGGCAGGTCGGCG-3′.
- Mitochondrial D-loop fragment (800-900 bp) was amplified with the primers HV2 described by Hoelzel et al., 1991, Mol. Biol. Evol., 8, 475-493, and the primer 5′-GGTGACTTGCATGTGTAAGTTCA-3′.
- the amplified fragments were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1 ⁇ TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- DNA yield of 300-500 ng was routinely obtained from fish epithelia, using the standard protocol and one sample test (Table 2). Mitochondrial DNA was nicely amplified using 5% of the isolated DNA.
Abstract
The present invention provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample. Where the method of the invention is used to isolate DNA, it may conveniently be couple with a further step to isolate RNA from the same sample.
Description
- The present application is a continuation of co-pending U.S. patent application Ser. No. 11/234,001 filed Sep. 23, 2005, which was a continuation of U.S. patent application Ser. No. 08/849,686 filed Aug. 21, 1997, which was a 35 U.S.C. § 371 national phase filing of international application No. PCT/GB95/02893, filed Dec. 12, 1995, which claimed priority to GB 9425138.6, filed Dec. 12, 1994.
- The present invention relates to the isolation of nucleic acid, and especially to the isolation of DNA or RNA from cells.
- The isolation of DNA or RNA is an important step in many biochemical and diagnostic procedures. For example, the separation of nucleic acids from the complex mixtures in which they are often found is frequently necessary before other studies and procedures e.g. detection, cloning, sequencing, amplification, hybridisation, cDNA synthesis etc. can be undertaken; the presence of large amounts of cellular or other contaminating material eg. proteins or carbohydrates, in such complex mixtures often impedes many of the reactions and techniques used in molecular biology. In addition, DNA may contaminate RNA preparations and vice versa. Thus, methods for the isolation of nucleic acids from complex mixtures such as cells, tissues etc. are demanded, not only from the preparative point of view, but also in the many methods in use today which rely on the identification of DNA or RNA eg. diagnosis of microbial infections, forensic science, tissue and blood typing, detection of genetic variations etc.
- In RNA identifications it is important for a conclusive diagnosis to be certain that the detected sequence is derived from an RNA molecule and not from genomic DNA contamination in the sample. For this reason, methods for the separation of RNA from DNA are important. Also, for RNA isolation rapid methods are required since RNA molecules usually are very unstable and rapidly degraded by RNases present in cells and body fluids. The quality of the RNA is probably the most important factor in determining the quality of the final results in protocols utilising mRNA, especially for cDNA synthesis. It is important to avoid DNA contamination of RNA preparations for a number of reasons. Firstly, DNA increases viscosity making sample handling difficult leading to poor RNA yield and also RNA of poor quality with the likelihood of DNA contamination. Also, DNA contamination may trap RNase enzymes and make downstream applications such as RT-PCR worthless.
- A range of methods are known for the isolation of nucleic acids, but generally speaking, these rely on a complex series of extraction and washing steps and are time consuming and laborious to perform. Moreover, the use of materials such as alcohols and other organic solvents, chaotropes and proteinases is often involved, which is disadvantageous since such materials tend to interfere with many enzymatic reactions and other downstream processing applications.
- Thus, classical methods for the isolation of nucleic acids from complex starting materials such as blood or blood products or tissues involves lysis of the biological material by a detergent or chaotrope, possibly in the presence of protein degrading enzymes, followed by several extractions with organic solvents eg. phenol and/or chloroform, ethanol precipitation, centrifugations and dialysis of the nucleic acids. The purification of RNA from DNA may involve a selective precipitation with LiCl or a selective isolation with acidic guanidinium thiocyanate combined with phenol extractions and ethanol precipitation. Not only are such methods cumbersome and time consuming to perform, but the relatively large number of steps required increases the risk of degradation, sample loss or cross-contamination of samples where several samples are simultaneously processed. In the case of RNA isolation, the risk of DNA contamination is relatively high.
- In purification of RNA, it is commonly desired to specifically isolate mRNA. Most mRNA purification strategies involve isolation of total RNA and fractionation of the isolated RNA. Preparation of high-quality mRNA is an important step in the analysis of gene structure and gene regulation.
- Most eukaryotic mRNAs have a poly(A)tail, typically about 50 to 300 nucleotides long. Such mRNA is referred to as polyadenylated or poly(A)+ mRNA. In separating this polyadenylated RNA from the non-adenylated RNA which accounts for 95% or more of a cell's total RNA, advantage is taken of this poly(A) tail and some type of affinity separation directed toward the poly(A) tail is performed. The conventional technology has involved purification of total RNA as a first step and selection of poly(A)+ RNA by affinity chromatography using oligo(dT)-cellulose as the second step. This strategy, is rather time-consuming and labour-intensive. An alternative strategy for mRNA purification is to use oligo(dT) linked to solid supports such as microplates, latex, agarose or magnetic beads.
- Over the past four years it has become increasingly popular to employ a magnetic bead assisted strategy for poly(A)+ RNA selection since such beads have proven to be favourable in mRNA manipulations. In many approaches, the yield and the quality of the products depends on how rapidly the mRNA can be purified from nucleases and other contaminants. By using the magnetic bead separation technology, pure, intact poly(A)+ RNA can be obtained rapidly either from total RNA preparations or more importantly, directly from crude lysates of solid tissues, cell or body fluids. The entire procedure can be carried out in a microfuge tube without phenol extractions or ethanol precipitations.
- One approach common in RNA purification, which may be used in conjunction with the solid phase approach is to carry out the lysis of the biological material and the subsequent hybridisation to oligo dT in LiCl and LiDS/SDS buffers, thereby avoiding extra steps such as phenol extraction or proteinase-K digestion. The whole direct mRNA isolation takes approximately 15 minutes and since the mRNA is stable for more than 30 minutes in the lysis buffer, this ensures the high quality of the mRNA purified. However, a disadvantage of this method is that mRNA per weight unit of tissue is affected by the amount of tissue used and above a critical threshold of lysed cells, the yield of mRNA decreases.
- Another common approach for direct mRNA purification is, as mentioned above, to use guanidinium isothiocyanate (GTC) and sarkosyl. A GTC-buffer system is preferred by most researchers due to the ability of this chaotropic salt to inhibit RNases. This may also be used in combination with the magnetic bead approach. However, the viscosity of cell lysates in 4M GTC is high and the beads are not effectively attracted by the magnet, resulting in an increased risk for DNA contamination, both for beads and other solid phases, and lower yields.
- More recently, other methods have been proposed which rely upon the use of a solid phase. In U.S. Pat. No. 5,234,809, for example, is described a method where nucleic acids are bound to a solid phase in the form of silica particles, in the presence of a chaotropic agent such as a guanidinium salt, and thereby separated from the remainder of the sample. WO 91/12079 describes a method whereby nucleic acid is trapped on the surface of a solid phase by precipitation. Generally speaking, alcohols and salts are used as precipitants.
- Although such methods speed up the nucleic acid separation process, there are disadvantages associated with the use of alcohols, chaotropes, and other similar agents. Chaotropes require to be used at high molarity, resulting in viscous solutions which may be difficult to work with, especially in RNA work. Amplification procedures such as PCR, and other enzyme-based reactions, are very sensitive to the inhibitory or otherwise interfering effects of alcohols and other agents. Moreover, the drying of the nucleic acid pellet which is necessary following alcohol precipitation and the problems with dissolving nucleic acids, are also known to lead to artifacts in enzyme-based procedures such as PCR. Since such procedures are now a mainstay of molecular biology, there is a need for improved methods of nucleic acid isolation, and particularly for methods which are quick and simple to perform and which avoid the use of chaotropic agents or alcohol precipitation. There is also a need for a method which allows for differentiation between RNA and DNA and permits a separate isolation of both types of nucleic acid from the same sample. The present invention seeks to provide such methods.
- In particular, it has now been found that nucleic acid may be isolated from a sample in a form suitable for amplification or other downstream processes, by a simple and easy to perform procedure which involves treating the sample with detergent and allowing the nucleic acid to bind to a solid support, whereupon the nucleic acid may be readily separated from the sample, eg. by removal of the support. The binding of the nucleic acid is independent of its sequence.
- In one aspect, the present invention thus provides a method of isolating nucleic acid from a sample, said method comprising contacting said sample with a detergent and a solid support, whereby soluble nucleic acid in said sample is bound to the support, and separating said support with bound nucleic acid from the sample.
- The nucleic acid may be DNA, RNA or any naturally occurring or synthetic modification thereof, and combinations thereof. Preferably however the nucleic acid will be DNA, which may be genomic, or, cDNA, and single or double stranded or in any other form.
- Where the method of the invention is used to isolate DNA, it may conveniently be coupled with a further step to isolate RNA from the same sample. The use of the method in such two-step RNA separations will be described in more detail below.
- The samples may be any material containing nucleic acid, including for example foods and allied products, clinical and environmental samples. However, the sample will generally be a biological sample, which may contain any viral or cellular material, including all prokaryotic or eukaryotic cells, viruses, bacteriophages, mycoplasmas, protoplasts and organelles. Such biological material may thus comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, protozoa etc. Representative samples thus include whole blood and blood-derived products such as plasma, serum and buffy coat, urine, feces, cerebrospinal fluid or any other body fluids, tissues, cell cultures, cell suspensions etc.
- The sample may also include relatively pure starting materials such as a PCR product, or semi-pure preparations obtained by other nucleic acid recovery processes.
- The nucleic acid-containing sample may, generally speaking, simply be contacted with the detergent, and a solid phase which may be added to the sample prior to, simultaneously with, or subsequently to the detergent. If necessary, this may be preceded by one or more separate steps to disrupt structural components such as cell walls or to achieve lysis. Procedures for achieving this are well known in the art. Thus, for example, although some cells eg. blood cells, may be lysed by the detergent alone, other cells, eg. plant or fungal cells or solid animal tissues may require more vigorous treatment such as, for example, grinding in liquid nitrogen, heating in the presence of detergent, alkaline lysis in the presence of detergent. For samples in the form of paraffin sections and such like, lysis (and melting of the paraffin) may be effected by heating, for example using a microwave oven (Banerjee, S. K. ea., 1995, Biotechniques 18: 769-773). Also, certain more compact tissues may require enzyme treatment, for example using proteinase K to obtain sufficient release of nucleic acid. The various components are mixed and simply allowed to stand for a suitable interval of time to allow the nucleic acid to bind to the support. Conveniently, if other agents such as enzymes eg. proteinase K are being used, they may be included in with the detergent. The support is then removed from the solution by any convenient means, which will depend of course on the nature of the support, and includes all forms of withdrawing the support away from the sample supernatant, or vice versa, for example centrifugation, decanting, pipetting etc.
- The conditions during this process are not critical, and it has been found convenient, for example, simply to mix the sample with the detergent in the presence of a solid phase, and allow it to stand at room temperature, for 5 to 20 minutes, before separating. As mentioned above, the reaction time is not critical and as little as 5 minutes is often enough. However, if convenient, longer periods may be used, eg. 0.5 to 3 hours, or even overnight. Mixing can be done by any convenient means, including for example simple agitation by stirring or vortexing. Also, if desired, higher or lower temperatures may be used, but are not necessary.
- The detergent may be any detergent, and a vast range are known and described in the literature. Thus, the detergent may be ionic, including anionic and cationic, non-ionic or zwitterionic. The term “ionic detergent” as used herein includes any detergent which is partly or wholly in ionic form when dissolved in water. Anionic detergents have been shown to work particularly well and are preferred. Suitable anionic detergents include for example sodium dodecyl sulphate (SDS) or other alkali metal alkylsulphate salts or similar detergents, sarkosyl, or combinations thereof.
- Conveniently, the detergent may be used in a concentration of 0.2 to 30% (w/v), eg. 0.5 to 30%, preferably 0.5 to 15%, more preferably 1 to 10%. For anionic detergents concentrations of 1.0 to 5% eg. 0.5 to 5% have been shown to work well.
- The detergent may be supplied in simple aqueous solution, which may be alkaline or acidic, or more preferably in a buffer. Any suitable buffer may be used, including for example Tris, Bicine, Tricine, and phosphate buffers. Conveniently, a source of monovalent cations, eg. a salt, may be included to enhance nucleic acid capture, although this is not necessary. Suitable salts include chloride salts, e.g. sodium chloride, lithium chloride etc. at concentrations of 0.1 to 1M, eg. 250 to 500 mM. As mentioned above, other components such as enzymes, may also be included.
- Other optional components in the detergent composition include chelating agents eg. EDTA, EGTA and other polyamino carboxylic acids conveniently at concentrations of 1 to 50 mM etc., reducing agents such as dithiotreitol (DTT) or β-mercaptoethanol, at concentrations of for example 1 to 10 mM.
- Preferred detergent compositions may for example comprise:
- 100 mM Tris-HCl pH 7.5
- 10 mM EDTA
- 2% SDS
- or:
- 100 mM TrisCl pH 7.5
- 10 mM EDTA
- 5% SDS
- 10 mM NaCl
- or:
- 100 mM TrisCl pH 7.5
- 500 mM LiCl
- 10 mM EDTA
- 1% LiDS
- The detergent functions in the method to lyse the nucleic acid containing material, eg. the cells and nuclei to release the nucleic acid. The detergent is also believed to help to disrupt the binding of proteins, eg. DNA-binding proteins, to the nucleic acid and to reduce the problem of contaminants in the sample sticking to the solid support.
- The solid support may be any of the well known supports or matrices which are currently widely used or proposed for immobilisation, separation etc. These may take the form of particles, sheets, gels, filters, membranes, fibers, capillaries, or microtitre strips, tubes, plates or wells etc.
- Conveniently the support may be made of glass, silica, latex or a polymeric material. Preferred are materials presenting a high surface area for binding of the nucleic acid. Although not wishing to be bound by theoretical considerations, it is believed that the nucleic acid binding process may be assisted by the nucleic acid “wrapping around” the support. Such supports will generally have an irregular surface and may be for example be porous or particulate eg. particles, fibres, webs, sinters or sieves. Particulate materials eg. beads are generally preferred due to their greater binding capacity, particularly polymeric beads.
- Conveniently, a particulate solid support used according to the invention will comprise spherical beads. The size of the beads is not critical, but they may for example be of the order of diameter of at least 1 and preferably at least 2 μm, and have a maximum diameter of preferably not more than 10 and more preferably not more than 6 μm. For example, beads of diameter 2.8 μm and 4.5 μm have been shown to work well.
- Monodisperse particles, that is those which are substantially uniform in size (eg. size having a diameter standard deviation of less than 5%) have the advantage that they provide very uniform reproducibility of reaction. Monodisperse polymer particles produced by the technique described in U.S. Pat. No. 4,336,173 are especially suitable.
- Non-magnetic polymer beads suitable for use in the method of the invention are available from Dyno Particles AS (Lillestrom, Norway) as well as from Qiagen, Pharmacia and Serotec.
- However, to aid manipulation and separation, magnetic beads are preferred. The term “magnetic” as used herein means that the support is capable of having a magnetic moment imparted to it when placed in a magnetic field, and thus is displaceable under the action of that field. In other words, a support comprising magnetic particles may readily be removed by magnetic aggregation, which provides a quick, simple and efficient way of separating the particles following the nucleic acid binding step, and is a far less rigorous method than traditional techniques such as centrifugation which generate shear forces which may degrade nucleic acids.
- Thus, using the method of the invention, the magnetic particles with nucleic acid attached may be removed onto a suitable surface by application of a magnetic field eg. using a permanent magnet. It is usually sufficient to apply a magnet to the side of the vessel containing the sample mixture to aggregate the particles to the wall of the vessel and to pour away the remainder of the sample.
- Especially preferred are superparamagnetic particles for example those described by Sintef in EP-A-106873, as magnetic aggregation and clumping of the particles during reaction can be avoided, thus ensuring uniform and nucleic acid extraction. The well-known magnetic particles sold by Dynal AS (Oslo, Norway) as DYNABEADS, are particularly suited to use in the present invention.
- Functionalised coated particles for use in the present invention may be prepared by modification of the beads according to U.S. Pat. Nos. 4,336,173, 4,459,378 and 4,654,267. Thus, beads, or other supports, may be prepared having different types of functionalised surface, for example positively charged or hydrophobic. Weakly and strongly positively charged surfaces, weakly negatively charged neutral surfaces and hydrophobic surfaces eg. polyurethane-coated have been shown to work well.
- It is also possible to use solid supports which have been modified to permit the selective capture of desired cells, viruses etc. containing the nucleic acid. Thus for example, supports carrying antibodies, or other binding proteins, specific for a desired cell type may be used. This may introduce a degree of selectivity to the isolation of the nucleic acid, since only nucleic acid from a desired target source within a complex mixture may be separated. Thus for example, such a support may be used to separate and remove the desired cell type etc. from the sample, following which, the detergent is added to achieve lysis, release of the nucleic acid, and binding to the support.
- The preparation of such selective cell capture matrices is well known in the art and described in the literature.
- Likewise, the support may be provided with binding partners to assist in the selective capture of nucleic acids. For example, complementary DNA or RNA sequences, or DNA binding proteins may be used, or viral proteins binding to viral nucleic acid. The attachment of such proteins to the solid support may be achieved using techniques well known in the art.
- Although not necessary, it may be convenient to introduce one or more washing steps to the isolation method of the invention, for example following separation of the support from the sample. In the case of magnetic beads, this may conveniently be done before releasing the DNA from the beads. Any conventional washing buffers or other media may be used. Generally speaking, low to moderate ionic strength buffers are preferred eg. 10 mM Tris-HCl at pH 8.0/10 mM NaCl. Other standard washing media, eg. containing alcohols, may also be used, if desired.
- Following the separation step, and any optional washing steps which may be desired, the support carrying the nucleic acid may be transferred eg. resuspended or immersed into any suitable medium eg. water or low ionic strength buffer. Depending on the support and the nature of any subsequent processing desired, it may or may not be desirable to release the nucleic acid from the support.
- In the case of a particulate solid support such as magnetic or non-magnetic beads, this may in many cases be used directly, for example in PCR or other amplifications, without eluting the nucleic acid from the support. Also, for many DNA detection or identification methods elution is not necessary since although the DNA may be randomly in contact with the bead surface and bound at a number of points by hydrogen bonding or ionic or other forces, there will generally be sufficient lengths of DNA available for hybridisation to oligonucleotides and for amplification.
- However, if desired, elution of the nucleic acid may readily be achieved using known means, for example by heating, eg. to 65° C. for 5 to 10 minutes, and following which the support may be removed from the medium leaving the nucleic acid in solution. Such heating is automatically obtained in PCR by the DNA denaturation step preceding the cycling program.
- If it is desired to remove RNA from DNA, this may be achieved by destroying the RNA before the DNA separation step, for example by addition of an RNase or an alkali such as NaOH.
- Alternatively, as mentioned above, the method of the invention may be used to separate sequentially DNA and RNA from the sample. It may also be used to remove DNA from a sample in an RNA purification procedure.
- Conveniently, the sequential separation may take place using two different solid phases, for example solid supports which can differentiate between DNA and RNA. Thus, such a method may comprise carrying out a first step separation to isolate DNA as described above. A further solid support can then be added to the sample to capture the RNA remaining in the sample, either by using a solid support that can bind the RNA or any remaining nucleic acid, or a solid support that can capture specific RNA molecules (eg. by carrying a complementary nucleic acid probe), or a subset of RNA molecules eg. polyadenylated RNA. In this way it is possible rapidly to isolate and separate DNA and RNA or subsets of both from the same sample. This may be useful, for example by measuring the isolated DNA to estimate the amount of cells used for RNA extraction, which will give a reference between different samples.
- However, the DNA isolation procedure of the invention may also readily be combined, as a preliminary step, with other conventional RNA purification procedures, for example DNA isolation with detergent according to invention may be carried out before a selective RNA precipitation step, for example using LiCl or before RNA separation using GTC and sarkosyl.
- In a representative procedure, the sample is lysed in the presence of detergent and the DNA is allowed to bind to a solid support, whereupon the DNA may readily be separated from the sample by removal of the support. If desired, the DNA can rapidly and easily be further handled for amplification or other downstream processes. The RNA may then be isolated. This can be by a solid phase based system as described above, including a repetition of the method of the invention, or by conventional techniques such as extractions, precipitations or affinity chromatography.
- A particularly advantageous embodiment of the invention is to use the isolation method of the invention to remove DNA from a sample prior to isolation of RNA, such that the viscosity of the lysed sample is reduced and a specific isolation of RNA molecules is favored which again reduces or avoids the possibility for DNA contamination of the RNA. Such a method also has the advantage of being quick to perform.
- The invention is advantageously amenable to automation, particularly if particles, and especially, magnetic particles are used as the support.
- The various reactants and components required to perform the method of the invention may conveniently be supplied in kit form. Such kits represent a further aspect of the invention.
- At its simplest, this aspect of the invention provides a kit for isolating nucleic acid from a sample comprising a solid support and one or more detergents.
- Optionally included in such a kit may be buffers, salts, lysis agents eg. proteinases, chelating agents and reducing agents.
- For isolation of RNA, the kits may further comprise means for isolating RNA eg. a second solid support for isolating RNA, for example a support provided with probes for capture of RNA eg. oligo dT or probes of complementary sequence to the desired target, or a chaotrope or selective precipitating agent.
- The invention will now be described in more detail in the following non-limiting Examples with reference to the drawings in which:
-
FIG. 1 shows as optical density scan of DNA isolated as described in Example 1 (ordinate shows absorbance (OD), abscissa shows wavelength (nM)). Maximum absorbance (0.427) at 257.6 nM; minimum absorbance (0.292) at 236.4 nM; at a threshold of 0.100; -
FIG. 2 shows gel electrophoresis of a sample of DNA isolated as described in Example 1 (lane 1: isolation; lane 2: .lamda. Hind III (molecular weight marker)); -
FIG. 3 shows agarose gel electrophoresis of the PCR product of Example 2 (lane 1: PCR product; lane 2: .lamda. Hind III; lane 3: negative PCR control); and -
FIG. 4 shows agarose gel electrophoresis of the PCR product of Example 5 (lane 1: .lamda. Hind III;lanes 2 and 3: isolations A and B respectively;lanes 4 and 5: negative control; lane 6: .lamda. Hind III). -
FIG. 5 show the comparison between traditionally isolated DNA and DNA isolated with Dynabeads DNA DIRECT. Panel I shows the amount of genomic DNA isolated from 10 μl of whole blood with Dynabeads DNA DIRECT including the optional elution step (lanes 1 and 2), with Dynabeads DNA DIRECT with the elution step omitted (lanes 3 and 4), and with traditional DNA isolation (lanes 5 and 6). The molecular weight marker inlane 7 is .lamda. HindIII. Panel II shows the integrity of DNA isolated by Dynabeads DNA DIRECT.Lanes Lanes Lane 3 is the negative control. -
FIG. 6 shows the reproducibility of Dynabeads DNA DIRECT. The figure shows five independent Dynabeads DNA DIRECT isolations from each of two donors. Half of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Molecular weight markers are .lamda. HindIII (lanes marked M) or 100 bp ladder (lane marked L). -
FIG. 7 shows the effect of different anticoagulants. The figure shows Dynabeads DNA DIRECT isolations from whole blood that is not anticoagulated and from blood anticoagulated with EDTA, citrate, or S heparin. The two isolations from blood with the same anticoagulant were performed on blood from different donors (A or B). One quarter of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, except for heparin, where half the DNA obtained from 5 μl is shown. 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure, except for heparin, where 20% of the isolated DNA was used as starting material. -
FIG. 8 shows the effect of sample storage conditions. Panel I shows Dynabeads DNA DIRECT isolations from EDTA blood that has been used fresh, refrigerated for 4 days, or frozen for 4 days. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Panel II shows Dynabeads DNA DIRECT isolations from citrate blood that has been used fresh or air dried and rehydrated. The two isolations from blood with the same storage conditions were performed on blood from different donors. Half of the DNA obtained from 10 μl of blood is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. -
FIG. 9 shows Dynabeads DNA DIRECT from bone marrow and culture cells. Panel I shows Dynabeads DNA DIRECT isolations from 1, 2 and 5 μl of bone marrow from each of two donors. A or B above the lanes denote the identity of the donor. Half of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 10% of the isolated DNA is shown in the lower part of the figure. Panel II shows two Dynabeads DNA DIRECT isolations from 4×105 Daudi cells. One tenth of the DNA obtained is shown in the upper part of the figure, 20% of the product from PCR reactions started with 1 μl of a total of 120 μl isolated DNA is shown in the lower part of the figure. The molecular weight marker is .lamda. HindIII for the genomic DNA and 100 bp ladder for the PCR products. -
FIG. 10 shows Dynabeads DNA DIRECT from formalin fixed, paraffin embedded material. Lane A is 20% of the PCR product from a reaction started with DNA isolated by DNA DIRECT from a formalin fixed, paraffin embedded section of liver. Lane M is molecular weight marker (100 bp ladder), lane B is positive control (PCR from 20 ng human DNA), and lane C is negative control (PCR from water). -
FIG. 11 shows Dynabeads DNA DIRECT for mRNA purification. mRNA was isolated from 1 million Daudi cells per sample with Dynabeads Oligo(dT)25 after removal of DNA with Dynabeads DNA DIRECT. Increasing amounts of DNA DIRECT Dynabeads were used to remove genomic DNA; 1 mg inlane lane lane lane 7 and 8. Lane 9 and 10 are controls where no DNA was removed before direct mRNA purification. The extra bands on the top of the picture show contaminating genomic DNA in lane 9 and 10. The two strong bands in all lanes represent ribosomal RNA. -
FIG. 12 shows the results of DNA isolation and PCR amplification from (A) bacteria, (B) fungi, (C) algae and (D) plants. For all samples, DNA was isolated with 200 μl DNA DIRECT (one sample test) and 20% of the isolated DNA and 10% of the PCR products were analysed by agarose electrophoresis. For bacteria, 2.5% of the isolated DNA was used per PCR reaction, for theother samples 5% was used. 16S rRNA regions were amplified from bacterial genomic DNA and from algae chloroplast DNA. From fungi- and algae genomic DNA, 18S rDNA were amplified. Amplification of the group I intron chloroplast trnL and parts of the genomic B15C gene are shown for plants. The negative controls are PCR on samples without DNA prepared in the same way as the other reactions. - DNA Isolation from Cell Culture
- 4×106 HL60 cells were washed twice in PBS and pelleted. The pellet was dissolved in 10 μl PBS, and 1 mg of Dynabeads® M-280* obtainable by autoclaving a suspension of Dynabeads® M-280 tosyl activated (available from DYNAL A/S, Oslo, Norway) in water) resuspended in 0.1 ml lysis buffer [5% SDS/10 mM TrisCl pH 8.0/1 mM EDTA] was added. This was followed immediately by the addition of 1 ml lysis buffer, and the suspension was incubated for 5 minutes at room temperature, after which the Dynabeads®, with bound DNA was attracted to a magnet and the liquid phase removed. The solid phase was then washed twice with 1 ml washing buffer [50 mM NaCl/10 mM TrisCl pH 8.0/1 mM EDTA]. Finally, the beads, with bound DNA, were resuspended in 0.1 ml water, and incubated for 5 minutes at 65° C. The beads were attracted to a magnet, and the liquid phase withdrawn. The liquid phase was then analyzed for its DNA content. Results from an optical density scan (
FIG. 1 ) are in accordance with pure DNA. The OD260/OD280 ratio is 1.72; pure DNA in water or TE has a ratio of 1.7-1.9. With pure DNA, the concentration can be determined from the OD260 of the solution. A 50 μg/ml solution has OD260=1.0. From the OD260 measurement (Table 1) of 0.436 (0.1 ml total volume, 10 mm light path), the yield can be calculated to 2.18 μg DNA, 82% of the 2.67 μg that was the estimated DNA content of the starting material. Gel electrophoresis of a sample of the isolated DNA (FIG. 2 ) shows that most of it is in a high molecular weight form (>20 kb).TABLE 1 PERKIN-ELMER LAMBDA BIO UV/VIS SPECTROMETER APPLICATION NO. 3: RATIO 260/280 NM WAVELENGTH SAMPLE CYCLE AUTOZERO DATA UNIT 004 15:50 260.0 nm 0.436 ABS 15:56 280.0 nm 0.253 ABS RATIO 1.723 RAT - Isolation of DNA from Whole Blood and Enzymatic Application without Elution
- 5 μl whole blood (EDTA blood) was lysed in 50
μl 5% SDS and 50 μg Dynabeads® M-280* in 5 μl of PBS was added. The lysate was incubated for 1 minute at room temperature before 0.5 ml TrisCl pH 7.5 was added. The lysate was then incubated for 1 minute further at room temperature before the beads with bound DNA were attracted to a magnet and the liquid phase removed. The beads were then washed once with 0.5 ml 10 mM TrisCl pH 7.5, before the beads with bound DNA was resuspended in 40 μl TE (10 mM TrisCl pH 8.0/1 mM EDTA). 4 μl of the isolation was used in starting material for PCR (GAPDH PCR as described in Example 7). The PCR reaction gave large amounts of product, as visualised on agarose gel electrophoresis (FIG. 3 ). 10 μl of a 50 μl PCR reaction was loaded on the gel. - Example 1 was repeated using the following combination of lysis buffers and washing buffers, and the following results were obtained:
Lysis buffer Washing buffer Result 2% SDS 50 mM NaCl/1 × TE +++ 2% SDS/1 × TE 50 mM NaCl/1 × TE +++ 2% SDS/1 × TE/10 mM NaCl 50 mM NaCl/1 × TE +++ 5% SDS 50 mM NaCl/1 × TE +++ 5% SDS/1 × TE 50 mM NaCl/1 × TE +++ 5% SDS/1 × TE/10 mM NaCl 50 mM NaCl/1 × TE +++ 1% LiDS/10 × TE/0.5 M LiCl 50 mM NaCl/1 × TE +++ 1% LiDS/10 × TE/0.5 M LiCl 150 mM LiCl/1 × TE +++ 5% LiDS 150 mM LiCl/1 × TE +++ 5% SDS 150 mM LiCl/1 × TE +++ 1% Sarcosyl 150 mM LiCl/1 × TE +++
1 × TE is 10 mM TrisCl pH 8.0/1 mM EDTA.
10 × TE is 100 mM TrisCl pH 8.0/10 mM EDTA.
where +++ indicates very good DNA isolation.
- Following the procedure of Example 1, similar results may be achieved using Dynabeads® M-450 uncoated (Dynal A/S, Oslo, Norway)
- Isolation of DNA from CD2 Positive Cells Obtained from Blood with Immunomagnetic Separation
- This experiment consisted of two identical isolations. 50 μl blood was mixed with 50 μl PBS [150 mM NaCl/10 mM NaH2PO4/Na2HPO4, pH 7.4] and 10 μl (4×106 beads) Dynabeads® M-450 Pan-T (CD2) (available from Dynal AS, Oslo, Norway). The mixture was then incubated for 30 minutes at room temperature with gentle tilting and rotation. The cell/beads complex was attracted to a magnet and the fluid withdrawn. The cell/beads complex was then washed four times in 200 μl PBS, before 200 g Dynabeads® M-280* (as above) and 2001 lysis buffer [100 mM Tris-HCl, pH 8.0/500 mM LiCl/10 mM EDTA, pH 8.01/1% LiDS] was added. The mixture was incubated for 5 minutes at room temperature, before the DNA/beads complex was attracted to a magnet, and the supernatant withdrawn. The DNA/beads complex washed twice with 200 μl washing buffer [10 mM Tris-Hcl, pH 8.0/150 mM LiCl/1 mM EDTA, pH 8.0] and resuspended in 50 μl water. After 5 minutes at 65° C., the beads were attracted to a magnet and the supernatant transferred to a new tube. 5 μl of the supernatant was used as template for polymerase chain reaction (GAPDH PCR as described in Example 7), which gave large amounts of product, as visualised on agarose gel electrophoresis (
FIG. 4 ). - Comparison of Yield and Integrity Between DNA Isolated by a Traditional Method and the Present Method
- Using a traditional method based on phenol extraction and ethanol precipitation, genomic DNA was isolated from 5 ml of EDTA anticoagulated blood. Four isolations from 10 μl of the same blood sample were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway, containing beads equivalent to Dynabeads® M-280* as described in Example 1). The DNA from two of the isolations was eluted for 5 minutes at 65° C., while the DNA from the other two isolations was left in the presence of the Dynabeads. All the DNA from the four Dynabeads DNA DIRECT isolations was loaded onto an agarose gel, as was 0.2% of traditionally isolated DNA. The fraction of the traditionally isolated DNA loaded corresponds to the yield from 10 μl of blood (0.2% of 5 ml).
- Traditional DNA isolation was performed according to the method of John and coworkers (John, S. W. M., G. Weitzner, R. Rosen and C. R. Scriver. 1991. A Rapid Procedure for Extracting Genomic DNA from Leukocytes. Nucl. Acid. Res. 19(2):408).
- With Dynabeads DNA DIRECT, lysis of the blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with 10 μl of blood in a 1.5 ml microcentrifuge tube (200 μg uncoated Dynabeads in Lysis/binding buffer). Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 μl of TE pH 8.0 (provided in the kit).
- When elution was performed, it consisted of heating the suspension to 65° C. for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.
- The DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The result of this experiment is shown in panel I of
FIG. 5 . The yield per μl blood is similar with the two methods (lane 1-4 vs lane 5-6), and very little DNA is lost during the elution step (lane 1-2 vs lane 3-4). The molecular weight of the DNA from both methods is more than 20 kb, as it runs slower than the 23.13 kb band of the .lamda. HindIII molecular weight marker. - DNA DIRECT was used to isolate DNA from ACD blood from two different donors, one male and one female. From each of the isolations, 10% was used as starting material for PCR amplification of an amplicon in the X-Y homologous amelogenin (AMXY) gene (Akane, A., K, Matsubara, H. Nakamura, S. Takahashi and K. Kimura. 1994. Purification of Highly Degraded DNA by Gel Filtration for PCR. BioTechniques 16 (2):235-238), as was 200 ng from each of two traditional DNA isolations.
- DNA DIRECT and traditional DNA isolation was performed as described in the first part of this example.
- All PCR reactions were performed in a 50 μl reaction volume, 10×PCR buffer (Perkin Elmer) was added to a final concentration of 1×, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers AMXY-1F (5′-CTGATGGTTGGCCTCAAGCCT-GTG-3′) and AMXY-4R (5′-TTCATTGTAAGAGCAAAGCAAACA-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the AMXY amplicon were 4 min at 94° C., 38×[30 sec at 94° C., 30 sec at 55° C., 1 min at 72° C.], 10 min at 72° C.
- 10 μl of the 50 μl PCR reactions were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The results of this experiment are shown in panel II of
FIG. 5 . The X-Y homologous amelogenin gene is known to be sensitive to DNA degradation (Akane et al 1994, supra). With increasing degradation, the 908 bp long X band gets progressively weaker as compared to the 719 bp long Y band. From panel II ofFIG. 5 it is apparent that the relative strength of the X and Y bands is comparable for DNA isolated with Dynabeads DNA DIRECT and the traditional method, indicating that the degree of degradation is the same with the two methods. The PCR reactions from traditionally isolated DNA gives somewhat more product than does the reactions from DNA DIRECT isolated DNA. The reason for this is that ten times more template is used in the PCR reactions from traditionally isolated DNA than in the PCR reactions from DNA DIRECT isolated DNA.Lysis/binding buffer: 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA - Five Independent DNA Isolations from Blood Samples from Each of Two Donors
- For this experiment, we used Dynabeads DNA DIRECT kit, which is commercially available from Dynal AS, Oslo, Norway. Buffer compositions are as described in example 6.
- Five DNA isolations were performed from each of two citrate treated blood samples of relatively low white blood cell counts (sample A: 3.6×106 cells/ml, sample B: 2.6×106 cells/ml).
- Lysis of the blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit). This resuspension was used for PCR and gel electrophoresis without any elution.
- From each isolation, 10% was used as starting material for PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. All PCR reactions were performed in a 50 μl reaction volume, 10×PCR buffer (Perkin Elmer) was added to a final concentration of 1×, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 pmol each of primers GAPDH-Forward (5′-ACAGTCCATGCCATCACTGCC-3′) and GAPDH-Reverse (5′-GCCTGCTTCACCACCCTTG-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94° C., 34×[30 sec at 94° C., 30 sec at 61° C., 1 min at 72° C.], 10 min at 72° C.
- Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The results of this experiment are shown in
FIG. 6 . No significant variation between the different isolations can be observed. Similar results were obtained with other coagulants as well as from donors with higher white blood cell counts. - DNA Isolation from Blood with Different Anticoagulants
- Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from untreated whole blood as well as blood anticoagulated with EDTA, Citrate or Heparin. From each type of starting material, two separate isolations were performed, with blood from different donors. The buffer components in the kit are as described in example 6.
- Lysis of the DNA containing cells from blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with 5 μl Heparin blood or 10 μl of other blood samples in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 20-40 μl of TE pH 8.0 (provided in the kit). We used 40 μl as the standard volume, but 20 μl if the starting material was Heparin blood.
- From each isolation, 10% (20% from the Heparin samples) was used as starting material for PCR amplification of an amplicon in the glyceraldehyde phosphate dehydrogenase (GAPDH) gene. PCR was performed directly on the suspension in TE, with the Dynabeads present. All PCR reactions were performed in a 50 μl reaction volume, 10×PCR buffer (Perkin Elmer) was added to a final concentration of 1×, dNTPs (Pharmacia) were added to a final concentration of 0.2 mM, and 1 unit of amplitaq (Perkin Elmer) was used per reaction. 5 μmol each of primers GAPDH-Forward (5′-ACAGTCCATGCCATCACTGCC-3′) and GAPDH-Reverse (5′-GCCTGCTTCACCACCTTCTTG-3′) were added per reaction. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600. PCR conditions for the GAPDH amplicon were 4 min at 94° C., 34×[30 sec at 94° C., 30 sec at 61° C., 1 min at 72° C.], 10 min at 72° C.
- 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 25% (50% from the Heparin samples) of the isolated genomic DNA. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The results of this experiment are shown in
FIG. 7 . As the isolations from Heparinized samples were from only 5 μl of blood, using 20% of the DNA from these isolations as starting material for PCR is comparable to using 10% from the other isolations, that are all from 10 μl blood. When this is taken into consideration, it is apparent that the type of anticoagulant used does not significantly affect the result. - In the experiment just described, Lithium Heparin was used. In this system, similar results are obtained with Lithium and Sodium Heparin, even though Lithium Heparin has been shown to have inhibitory effects in other systems (Panaccio, M., M. Georgesz and A. M. Lew. 1993. FOLT PCR: A Simple PCR Protocol for Amplifying DNA Directly from Whole Blood. BioTechniques 14(3): 238-243). DNA DIRECT also performs well on blood anticoagulated with ACD (panel II of
FIG. 5 ) or CPD (data not shown). - Isolation of DNA from Blood Samples Stored Under Different Conditions
- Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from EDTA blood from two different donors: What was remaining of the blood samples were then divided into two, one part that was stored at +4° C. and one that was stored at −20° C. After 4 days, the frozen samples were thawed, and DNA was isolated from both the frozen samples and the samples that had been kept at +4° C. The buffer components of the kit are as described in example 6.
- Lysis of the blood was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with blood in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
- From each of the 6 isolations (fresh, refrigerated, and frozen), 10% was used as starting material for PCR amplification of the GAPDR amplicon as described in example 8. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on the gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The results of this experiment are shown in panel I of
FIG. 8 . No adverse effect of 4 days storage at +4 or −20° C. was observed in this system. - Using Dynabeads DNA DIRECT as described earlier in this example, DNA was isolated from two citrate treated blood samples, and from the same two samples 10 μl was spotted on a plastic surface and allowed to air dry at room temperature. The dried blood spots were transferred to 1.5 ml tubes, 40 μl PBS was added, and the tubes were left at room temperature with gentle agitation for 90 min, before DNA was isolated with Dynabeads DNA DIRECT. From each of the 4 isolations (fresh and dried), 10% was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on the gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The results of this experiment are shown in panel II of
FIG. 8 . The yield from dried blood is good and the isolated DNA is suitable for PCR. - DNA Isolation from Bone Marrow and Culture Cells
- DNA Isolations from Bone Marrow
- 1, 2, and 5 μl of heparinized bone marrow from each of two healthy donors were used as starting material for DNA isolation with DNA DIRECT. The buffer components are as described in example 6. Lysis of the bone marrow was obtained by mixing 200 μl (one sample test) of Dynabeads DNA DIRECT with 1-5 μl of heparinized bone marrow in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E(MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit). Both PCR and agarose gel electrophoresis was performed directly on the suspension in TE, with the Dynabeads present.
- From each of the 6 isolations, 10% was used as starting material for PCR amplification of the GAPDH amplicon as is described in example 8.
- Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 50% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The results of this experiment are shown in panel I of
FIG. 9 . It is apparent from panel I ofFIG. 9 that the yield per volume starting material is higher from bone marrow than from blood (FIGS. 5-8 ). This is to be expected, since the concentration of DNA containing cells is much higher in bone marrow than in blood. 5 μl of bone marrow is close to the upper limit of what can be handled by 1 sample test of DNA DIRECT. A good correlation between sample size and DNA yield is observed in the 1 to 5 μl sample size interval, but even the yield from 1 μl is sufficient for at least 10 PCR reactions. - DNA Isolation from Cultured Cells
- Two samples of 4×105 Daudi cells were used as starting material for DNA isolation with DNA DIRECT. DNA isolation from 4×105 cultured cells (cell line Daudi) was performed as described above, except that 1 ml (five sample tests) of Dynabeads DNA DIRECT was used. Accordingly, the washing steps were performed in 1 ml washing buffer. The DNA/Dynabeads complex was resuspended in 120 μl TE, and as for bone marrow, no elution step was performed after the resuspension.
- From each of the isolations, 1 μl of a total of 120 μl was used as starting material for PCR amplification of the GAPDH amplicon, as described in Example 8.
- Both genomic DNA and PCR products were visualised on ethidium bromide stained 1.5% agarose gels. 10 μl of the 50 μl reaction was loaded on to an agarose gel, as was 10% of the isolated genomic DNA. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The results of this experiment are shown in panel II of
FIG. 9 , demonstrating that at least 120 PCR reactions may be run from an isolation of this scale. - Isolation of DNA from a Formalin Fixed, Paraffin Embedded Section of Liver
- Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway) was used to isolate DNA from a formalin fixed, paraffin embedded section of liver. The buffer components of the kit and the bead concentration are as described in example 6.
- Excess paraffin was removed from the edges of the sample with a scalpel blade. Lysis of the sample was obtained by adding 200 μl (one sample test) of Dynabeads DNA DIRECT to the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 minutes to allow adsorption of genomic DNA to the Dynabeads. The lysate, containing DNA and Dynabeads was transferred to a fresh tube, leaving cell debris and paraffin behind.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 10 μl of sterile water. This suspension, with the Dynabeads present, was used as starting material for PCR amplification of the GAPDH amplicon as described in example 8. The PCR product was visualised on an ethidium bromide stained 1.5% agarose gel. 10 μl of the 50 μl reaction was loaded on the gel. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film. The result of this experiment is shown in
FIG. 10 . PCR amplifiable material has clearly been obtained from the formalin fixed, paraffin embedded section of liver. - Removal of Genomic DNA with DNA DIRECT Prior to mRNA Isolation
- mRNA was isolated from 1 million Daudi cells per sample. The cells were lysed in 0.75 ml Lysis/binding buffer with DNA DIRECT Dynabeads present in the buffer. The samples were incubated for 5 minutes and the DNA-Dynabead complexes were collected by applying a Dynal MPC-E magnet for 2 minutes. Different amounts of DNA DIRECT beads were used to remove genomic DNA; 1, 2, 5 and 10 mg per sample (
FIG. 11 ). - The lysate from each sample was transferred to new tubes with 1 mg Dynabeads Oligo(dT)25 according to standard procedure (Dynals mRNA DIRECT kit protocol). The Dynabeads were mixed with the lysate to capture the polyadenylated mRNA by hybridisation for 5 minutes at room temperature. The mRNA-Dynabead complexes were collected with the MPC-E magnet by placing the tubes in the magnetic stand for 2 minutes. The solution was removed and discarded. Washing solution with LiDS (0.75 ml) was added and the beads were washed thoroughly by pipetting up and down. The mRNA-Dynabead complexes were collected with the magnet, and the washing procedure was repeated once with washing buffer with LiDS and twice with washing buffer without detergent. Finally, the purified mRNA was eluted from the Dynabeads in 20
μl 5 mM Tris-HCl pH 7.5 buffer, by incubation at 65° C. for 2 minutes. The eluates were analysed by non-denaturing gel electrophoresis in a 1.0 t agarose gel with ethidium bromide.FIG. 11 shows the results from this experiment. - The EtBr-staining reveals both double-stranded DNA and rRNA due to secondary structure. The two ribosomal RNA bands are clearly visible in all lanes. In Lane 9-10 in
FIG. 11 , some genomic DNA is present as contamination after the mRNA purification procedure. In the recommended mRNA procedure from DYNAL, a DNA-shearing step is introduced after cell lysis, to reduce the possibility of DNA contamination. By using DNA removal with DNA DIRECT beads this shearing step is not necessary.Lysis/binding buffer: 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer with LiDS: 0.15 M LiCl 0.1% LiDS 10 mM Tris-HCl pH 8.0 1 mM EDTA Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mM EDTA - Universal Method for DNA Isolation
- PCR-Ready DNA from Bacteria, Fungi, Algae, Plants and Vertebrates
- E. coli and Baceillus cereus were grown overnight at 37° C. in LB medium, Agrobacterium tumefaciens was grown overnight in YEB medium for about 40 hours at 28° C. (Sambrook, J. et al., 1989, Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbour Laboratory, NY.). Cyanobacteria and Prochlorthrix were grown in NIVA medium for 14 days at 18° C. using an illumination of 20 micro Einstein (Norwegian Institute of Water Research, 1991, Culture collection of algae). 20-200 million bacteria or 450,000 cyanobacteria were used per DNA isolation.
- Agar plates containing 2% malt extract was used for mycelia growth and incubated for 14 days at room temperature. Mycelia was isolated by scraping the surface of the agar plates with a spatula. Fungi fruitbodies were obtained from natural populations. In the range of 1-3 mg air dried and 3-20 mg fresh fungi fruitbodies were used per DNA isolation.
- Bakers yeast Saccharomyces cerevisiae was obtained from a commercial supplier. Algae were cultured under illumination in IMR-medium for 7 days (Eppley, R et al., 1967, Exp. Mar. Biol. Ecol. 1, 191-208). Fresh leaves from Arabidopsis thaliana and barley (Hordeum vulgare) were picked from young plants (3 weeks old). Epithelia were obtained from perch (Perca fluvatilis) fins. About 1 mg wet weight yeast, 30-100 mg young plant leaves and 100-400 mg perch were used per DNA isolation.
- Multicellular tissues with rigid cell walls were mechanically broken to increase DNA yield. Fungi fruitbodies were ground with forceps for about 2 minutes. Plant leaves were homogenised for 2 minutes in liquid nitrogen with a pestle (Kontes Scientific Instruments, Vineland, N.J., USA). For all other samples no mechanical work was required for cell breakage.
- DNA Isolation
- DNA isolations were performed using Dynabeads DNA DIRECT (kit, commercially available from Dynal AS, Oslo, Norway). Lysis of the cells and organisms were obtained by mixing 200 μl of Dynabeads DNA DIRECT (200 μg uncoated Dynabeads in Lysis/binding buffer) with the sample in a 1.5 ml microcentrifuge tube. Lysates were then left on the bench at room temperature for 5 to 15 minutes to allow adsorption of genomic DNA to the Dynabeads. For some bacteria and for plants, incubation at 65° C. for 15 minutes was used to improve lysis before the adsorption step.
- The DNA/Dynabeads complex was attracted to a magnet (Dynal's Magnetic Particle Collector E (MPC-E)), and the lysate was aspirated and discarded.
- The complex was then washed twice in washing buffer (one of the kit components) by attracting it to a Dynal MPC and discarding the supernatant. Finally, the complex was resuspended in 40 μl of TE pH 8.0 (provided in the kit) by vigorous pipetting. Elution was performed by heating the suspension to 65° C. for five minutes and then attracting the beads to a magnet. The DNA-containing aqueous phase was then withdrawn and used for the experiments.
- The DNA was visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
Lysis/binding buffer: 0.5 M LiCl 1% LiDS 0.1 M TrisCl pH 7.5 10 mM EDTA 5 mM dithiothreitol (DTT) Washing buffer: 0.15 M LiCl 10 mM Tris-HCl pH 8.0 1 mm EDTA - For an evaluation of the yield from the DNA DIRECT isolation protocol, standard phenol/chloroform based methods were used. Algae, vertebrate and bacterial DNA were isolated with the protocol described by Sambrook, J. et al., 1989, supra. Cyanobacteria were homogenized with alumina type A-5 (Sigma Chemicals Co., St. Louis, USA) before isolation to ensure complete lysis. Plant and fungi DNA were isolated with the protocol described by Scot, O. R. and Bendich, A. J., 1994, in “Plant Molecular Biology Manual”, page D1: 1-8, Kluwer Academic Publisher, Belgium. PCR Amplifications
- For each sample type the reproducibility was tested by using separate DNA isolations, serial DNA dilutions and multiple PCR assays. DNA isolation reagents and PCR reagents were controlled for absence of contamination in each separate experiment. All PCR reactions were performed in a 50 μl reaction volume containing; μmoles primers, 200 μM dNTP, 10 mM Tris-HCl pH 8.8, 1.5 mM MgCl2, 50 mM KCl, 0.1% Triton X-100, 1 Unit DynaZyme thermostable polymerase (Finnzymes Oy, Finland) and 0.1-5 μl of isolated DNA. PCR was performed on a Perkin Elmer GeneAmp PCR System 9600.
- Amplicons and Oligonucleotide Primer
- All PCR reactions were started with a DNA denaturation step at 94-97° C. for 3 to 5 minutes and ended with an extension step at 72° C. for 5 minutes.
- Bacteria and Algae:
- The amplicon was a 16S rRNA region corresponding to E. coli base 334 to 939 according to IUD numbering from bacteria and algae chloroplasts (Brosius, J., et al., 1978, Proc. Natl. Acad. Sci., USA, 57, 4801-4805).
- Primers:
CC 5′-TGTAAAACGACGGCCAGTCCAGACTCCTACGGGAGGCAGC-3′ CD 5′-CTTGTGCGGGCCCCCGTCAATTC-3′ - Primer CC has a 5′ end complementary to −21 M13 universal primer, making it suitable for direct DNA sequencing. Amplification: 30 cycles of 96° C. for 15 seconds and 70° C. for 2 minutes.
- Algae:
- An 18S rRNA region was amplified with the primers A and B described by Medlin et al., 1990, Gene, 71, 491-499.
- Amplification:
- 35 cycles of 94° C. for 30 seconds, 50° C. for 1 minute and 72° C. for 1 minute.
- Fungi:
- A 18S rRNA region (ca. 600 bp.) was amplified with the primers NS3 and NS4 as described by White et al., 1990. In “PCR Products, a Guide to Methods and Applications” by Innis, M. A. et al., page 315-322, Academic Press, New York.
- Amplification:
- 5 cycles of 94° C. for 30 seconds, 53° C. for 30 seconds and 72° C. for 1 minute; followed by 25 cycles of 94° C. for 30 seconds, 50° C. for 30 seconds increasing with 15 seconds for each cycle, and 72° C. for 1 minute.
- Plants:
- The tRNL group I intron in chloroplasts were amplified with the primers C and D described by Fangan et al., 1994, BioTechniques 16, 484-494.
- Amplification:
- 30 cycles of 94° C. for 30 seconds, 55° C. for 30 seconds and 72° C. for 1 minute.
- A part of the Arabidopsis thaliana gene BI5C (800 bp) was amplified with the primers:
5′-CGGGATCCCTAGGAGACACGGCCG-3′ and 5′-GGAATTCGATCGGCGGTCTTGAAAC-3′ - Amplification:
- 35 cycles of 94° C. for 30 seconds, 59° C. for 30 seconds and 72° C. for 1 minute.
- A part of the Barley gene Bl5C (800 bp) was amplified with the
primers 5′-5′-CGGATCCCGTCATCCTCTTCTCGCACCCC-3′ and 5′-GGAATTCCCTTCTTGGAGGGCAGGTCGGCG-3′. - Amplification:
- 35 cycles of 94° C. for 30 seconds, 60° C. for 30 seconds and 72° C. for 1 minute.
- Perch:
- Mitochondrial D-loop fragment (800-900 bp) was amplified with the primers HV2 described by Hoelzel et al., 1991, Mol. Biol. Evol., 8, 475-493, and the
primer 5′-GGTGACTTGCATGTGTAAGTTCA-3′. - Amplification:
- 30 cycles of 96° C. for 1 minute, 52° C. for 2 minutes and 72° C. for 2 minutes.
- The amplified fragments were visualised on ethidium bromide stained 1.5% agarose gels. Electrophoresis was performed in 1×TAE buffer, and the results were documented with a DS34 Polaroid camera and Polaroid 667 film.
- The results of the experiments are shown in
FIG. 12 and Table 2. - Bacteria:
- The standard protocol gave DNA yields in the range of 100-1000 ng for the bacteria tested (
FIG. 12A ). For some Cyanobacteria there was a substantial increase in DNA yield (from 500 ng to more than 1 mg) by improving the lysis with an extra initial incubation step at 65° C. for 15 minutes. In all cases, good amplifications were obtained by using 0.25% of the isolated DNA. - Fungi:
- The highest DNA yield was obtained from dried fruit-bodies (300-500 ng) compared with fresh fruit bodies (100-200 ng) (
FIG. 12B ). Mycelia gave low DNA recovery probably due to low number of cells per sample. However, inmost cases 5% of the isolated DNA was enough to give nice PCR products (Table 2,FIG. 12B ). For fruit bodies, 0.5-5% of DNA was used for each PCR. - Algae:
- All algae tested gave DNA yield in the range of 200-400 ng using the standard protocol and 1 DNA DIRECT sample test (Table 2,
FIG. 12C ). Nice PCR results were obtained both for amplification of genomic DNA and chloroplast DNA by using 5% of the isolated DNA per PCR reaction. - Plants:
- To obtain good DNA yield from plant leaves homogenization in liquid nitrogen was necessary. An extra initial incubation step at 65° C. for 15 minutes also improved the results (
FIG. 12D ). Nice PCR results were obtained both for amplification of genomic DNA and chloroplast DNA, when 5% of the isolated DNA was used per PCR reaction. - Fish:
- DNA yield of 300-500 ng was routinely obtained from fish epithelia, using the standard protocol and one sample test (Table 2). Mitochondrial DNA was nicely amplified using 5% of the isolated DNA.
- PCR products from all species tested could easily be directly sequenced by solid-phase sequencing (Hultman et al., 1989, Nucleic Acids Res., 17, 4937-4946).
TABLE 2 DNA isolation and PCR amplification from different organisms DNA Amplicon PCR Species Sample yield Gen. Org. productd Bacteria Bacillus sereus gram pos. fresh +++ 16S +++ AH 75a E. coli gram pos. fresh +++ 16S +++ NovaBlue A. tumefaciens gram neg. fresh +++ 16S +++ GV 310Planlaothrix gram neg. fresh +++ 16S +++ agardhill Cyanobacteria N-C29 P. prolifica gram neg. fresh +++ 16S +++ N-C320 Cyanobacteria Microstysis gram neg. fresh +++ 16S +++ aruginosa Cyanobactena N-C 43 M. aruginosa gram neg. fresh +++ 16S +++ N-C 228/1 Cyanobacteria Anabana bory gram neg. frozen +++ 16S ++ N-C 246 Cyanobacteria Phomidium sp gram neg. frozen +++ 16S ++ N-C 177 Cyanobacteria Apha- gram neg. frozen +++ 16S +++ nizomenon sp Cyanobacteria N-C 103 P. hollandica gram neg. frozen ++ 16S +++ N 5/89prochlorothrix Fungi Corrinarius basidlomycetes d. fruith +++ 16S +++ sanguineus Corinarius basidlomycetes d. fruith nt 16S +++ gentillis Rusula inegra basidlomycetes f. fruith ++ 16S +++ Laccaria ascomycetes f. mycel + 16S +++ bicolor Triharia ascomycetes f. mycel nt 16S +++ ochroleuca Verjahinia ascomycetes f. mycel nt 16S +++ cahhae Peziza yeast f. mycel nt 16S +++ vesiculosa Saccharomyces yeast fresh + 16S +++ cervisiae Algae Gyrodinum dinoflagellates fresh +++ 16S/16S +++/+++ aureolum Hetrocania dinoflagellates fresh +++ 16S/16S +++/+++ triguera Scripsiella dinoflagellates fresh +++ 16S/16S +++/+++ prochiden Ceranium dinoflagellates fresh +++ 16S +++ stricum Chorella dinoflagellates fresh +++ 16S +++ vulgaris Clamydomonas chlorophyta fresh +++ 16S +++ reinardii Callacanius phacophycease fresh +++ 16S +++ ustilla Chryso- crysophycease fresh +++ 16S +++ chromulina polyelepis Plants Hordum monocot leaf +++ B15C/trnL +++/+++ vulgare (barley) Arabidopsis dicot leaf +++ B15C/trnL +++/+++ thaliana Vertebrates Perca fish ep. +++ D-loop +++ fubvatillis (perch)
a A. rumerifaciens = Aghrobacterium tumefaciens, P. hollandica = Prochlorothrix hollandica.
bd. fruitb = dried fruitbodies, f. mycelia = fresh mycalia, ep. = epithelium.
cApproximate DNA yields relalive to standard phenol/chloroform isolations; +++: >80%, ++: >10%, +: >1%, nt. = not tested.
dGen. = genomic DNA, Org. = organelle DNA from chloreplasts (algae and plants) and mitochondria (fish).
eAmplicons as described in example 13.
Claims (20)
1. A method of isolating genomic DNA from a sample comprising cells, wherein the genomic DNA is present in the cells, the method comprising (a) contacting the sample with a solid support comprising an organic polymer, wherein the solid support selectively binds the cells, (b) contacting the cells bound to the solid support with a detergent in the absence of any chaotropic agent, whereby soluble genomic DNA becomes bound to the support in a sequence-independent manner in the presence of the detergent and absence of any chaotropic agent, and (c) separating the support with bound genomic DNA from the sample.
2. The method of claim 1 , wherein the solid support comprises an antibody or binding protein specific for the cells.
3. The method of claim 1 , wherein the solid support comprises an antibody specific for CD2 positive cells.
4. The method of claim 1 , wherein the detergent is anionic.
5. The method of claim 1 , wherein the detergent is sodium dodecyl sulphate, or another alkali metal alkylsulphate salt, or sarkosyl.
6. The method of claim 1 , wherein the concentration of detergent is 0.2% to 30% (w/v).
7. The method of claim 1 , wherein the detergent is contained in a composition additionally comprising one or more monovalent cations, chelating agents or reducing agents.
8. The method of claim 1 , wherein the detergent is used in alkaline solution.
9. The method of claim 1 , wherein the solid support is particulate.
10. The method of claim 1 , wherein the solid support comprises magnetic beads.
11. The method of claim 1 , wherein the solid support has a hydrophobic surface.
12. The method of claim 1 , wherein the genomic DNA is eluted from the support, following separation from the sample.
13. The method of claim 12 , wherein the genomic DNA is eluted by heating.
14. The method of claim 1 , wherein the organic polymer is polyurethane.
15. The method of claim 1 , wherein the organic polymer is polystyrene.
16. The method of claim 1 , wherein the organic polymer is latex.
17. The method of claim 1 , wherein the solid support comprises superparamagnetic polystyrene beads.
18. The method of claim 1 , wherein the solid support is porous.
19. The method of claim 1 , further comprising the step of detecting, hybridizing, amplifying or quantifying the bound genomic DNA after the separating step.
20. A method of isolating RNA and genomic DNA from a sample comprising cells, wherein the RNA and genomic DNA are present inside the cells, the method comprising (a) contacting the sample with a solid support comprising an organic polymer, wherein the solid support selectively binds the cells, (b) contacting the cells bound to the support with a detergent in the absence of any chaotropic agent, whereby soluble genomic DNA in the sample is bound to the support in a sequence-independent manner in the presence of the detergent and absence of any chaotropic agent; (c) separating the support with bound genomic DNA from the sample; and (d) isolating RNA from the sample.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/671,426 US20070190559A1 (en) | 1994-12-12 | 2007-02-05 | Isolation of nucleic acid |
US12/054,332 US7989614B2 (en) | 1994-12-12 | 2008-03-24 | Isolation of nucleic acid |
US12/130,926 US20090068724A1 (en) | 1994-12-12 | 2008-05-30 | Isolation of Nucleic Acid |
US12/130,959 US20090149646A1 (en) | 1994-12-12 | 2008-05-30 | Isolation of Nucleic Acid |
US13/160,428 US8691969B2 (en) | 1994-12-12 | 2011-06-14 | Isolation of nucleic acid |
US14/183,999 US20140291576A1 (en) | 1994-12-12 | 2014-02-19 | Isolation of nucleic acid |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9425138.6 | 1994-12-12 | ||
GBGB9425138.6A GB9425138D0 (en) | 1994-12-12 | 1994-12-12 | Isolation of nucleic acid |
US08/849,686 US20040215011A1 (en) | 1994-12-12 | 1995-12-12 | Isolation of nucleic acid |
PCT/GB1995/002893 WO1996018731A2 (en) | 1994-12-12 | 1995-12-12 | Isolation of nucleic acid |
US11/234,001 US7173124B2 (en) | 1994-12-12 | 2005-09-23 | Isolation of nucleic acid |
US11/671,426 US20070190559A1 (en) | 1994-12-12 | 2007-02-05 | Isolation of nucleic acid |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/234,001 Continuation US7173124B2 (en) | 1994-12-12 | 2005-09-23 | Isolation of nucleic acid |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/054,332 Continuation US7989614B2 (en) | 1994-12-12 | 2008-03-24 | Isolation of nucleic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070190559A1 true US20070190559A1 (en) | 2007-08-16 |
Family
ID=10765877
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/849,686 Abandoned US20040215011A1 (en) | 1994-12-12 | 1995-12-12 | Isolation of nucleic acid |
US11/234,001 Expired - Fee Related US7173124B2 (en) | 1994-12-12 | 2005-09-23 | Isolation of nucleic acid |
US11/671,426 Abandoned US20070190559A1 (en) | 1994-12-12 | 2007-02-05 | Isolation of nucleic acid |
US12/054,332 Expired - Fee Related US7989614B2 (en) | 1994-12-12 | 2008-03-24 | Isolation of nucleic acid |
US12/130,926 Abandoned US20090068724A1 (en) | 1994-12-12 | 2008-05-30 | Isolation of Nucleic Acid |
US12/130,959 Abandoned US20090149646A1 (en) | 1994-12-12 | 2008-05-30 | Isolation of Nucleic Acid |
US13/160,428 Expired - Fee Related US8691969B2 (en) | 1994-12-12 | 2011-06-14 | Isolation of nucleic acid |
US14/183,999 Abandoned US20140291576A1 (en) | 1994-12-12 | 2014-02-19 | Isolation of nucleic acid |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/849,686 Abandoned US20040215011A1 (en) | 1994-12-12 | 1995-12-12 | Isolation of nucleic acid |
US11/234,001 Expired - Fee Related US7173124B2 (en) | 1994-12-12 | 2005-09-23 | Isolation of nucleic acid |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/054,332 Expired - Fee Related US7989614B2 (en) | 1994-12-12 | 2008-03-24 | Isolation of nucleic acid |
US12/130,926 Abandoned US20090068724A1 (en) | 1994-12-12 | 2008-05-30 | Isolation of Nucleic Acid |
US12/130,959 Abandoned US20090149646A1 (en) | 1994-12-12 | 2008-05-30 | Isolation of Nucleic Acid |
US13/160,428 Expired - Fee Related US8691969B2 (en) | 1994-12-12 | 2011-06-14 | Isolation of nucleic acid |
US14/183,999 Abandoned US20140291576A1 (en) | 1994-12-12 | 2014-02-19 | Isolation of nucleic acid |
Country Status (9)
Country | Link |
---|---|
US (8) | US20040215011A1 (en) |
EP (1) | EP0796327B1 (en) |
JP (1) | JP3787354B2 (en) |
AT (1) | ATE272110T1 (en) |
AU (1) | AU706211B2 (en) |
CA (1) | CA2207608C (en) |
DE (1) | DE69533317T2 (en) |
GB (1) | GB9425138D0 (en) |
WO (1) | WO1996018731A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009040444A1 (en) * | 2007-09-28 | 2009-04-02 | Mole Genetics As | Rna isolation method |
US20110104157A1 (en) * | 2008-04-04 | 2011-05-05 | Chugai Seiyaku Kabushiki Kaisha | Liver cancer drug |
US7989614B2 (en) | 1994-12-12 | 2011-08-02 | Invitrogen Dynal As | Isolation of nucleic acid |
US8110351B2 (en) | 2002-01-16 | 2012-02-07 | Invitrogen Dynal As | Method for isolating nucleic acids and protein from a single sample |
Families Citing this family (162)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2965131B2 (en) | 1995-07-07 | 1999-10-18 | 東洋紡績株式会社 | Magnetic carrier for nucleic acid binding and nucleic acid isolation method using the same |
DE69734263T2 (en) * | 1996-07-12 | 2006-07-13 | Toyo Boseki K.K. | Process for isolating ribonucleic acids. |
US6143496A (en) | 1997-04-17 | 2000-11-07 | Cytonix Corporation | Method of sampling, amplifying and quantifying segment of nucleic acid, polymerase chain reaction assembly having nanoliter-sized sample chambers, and method of filling assembly |
GB9709728D0 (en) * | 1997-05-13 | 1997-07-02 | Dynal As | Single step method |
WO1999013976A1 (en) | 1997-09-17 | 1999-03-25 | Gentra Systems, Inc. | Apparatuses and methods for isolating nucleic acid |
DE69937631T2 (en) * | 1998-02-02 | 2008-10-30 | Qiagen North American Holdings, Inc. | COMPOSITION AND METHODS FOR USING A LYSIS MATRIX FOR ISOLATION OF DNA |
DE69938774D1 (en) * | 1998-02-02 | 2008-07-03 | Qiagen North American Holdings | METHOD OF ISOLATING, AMPLIFYING AND CHARACTERIZING DNA |
CA2319665C (en) * | 1998-02-02 | 2010-06-29 | Gentra Systems, Inc. | Processes for isolating, amplifying and characterizing dna |
US6534262B1 (en) | 1998-05-14 | 2003-03-18 | Whitehead Institute For Biomedical Research | Solid phase technique for selectively isolating nucleic acids |
US6291179B1 (en) * | 1998-09-10 | 2001-09-18 | Whatman Plc | Product and method for separation of a sample containing multiple sources of genetic material using a solid medium |
US5973138A (en) * | 1998-10-30 | 1999-10-26 | Becton Dickinson And Company | Method for purification and manipulation of nucleic acids using paramagnetic particles |
FI990082A0 (en) * | 1999-01-18 | 1999-01-18 | Labsystems Oy | Purification process using magnetic particles |
US7790865B1 (en) | 1999-02-02 | 2010-09-07 | Qiagen North American Holdings, Inc | Eluting reagents, methods and kits for isolating DNA |
EP1173623B1 (en) * | 1999-03-11 | 2008-06-25 | Whatman, Inc. | Solid medium and process for the storage and rapid purification of nucleic acid |
CA2370656A1 (en) * | 1999-04-21 | 2000-10-26 | Mitchell T. Gore | Magnetic dna extraction kit for plants |
ES2258429T3 (en) * | 1999-07-15 | 2006-09-01 | Qiagen Gmbh | METHODS TO SEPARATE SUBSTRATES IN PARTICLES OF A SOLUTION, AT THE TIME THAT THE LOSS OF PARTICLES IS MINIMIZED. |
US6936414B2 (en) * | 1999-12-22 | 2005-08-30 | Abbott Laboratories | Nucleic acid isolation method and kit |
GB0001450D0 (en) | 2000-01-21 | 2000-03-08 | Genpoint As | Cell isolation method |
GB0013658D0 (en) * | 2000-06-05 | 2000-07-26 | Dynal Asa | Nucleic acid isolation |
US7011943B2 (en) * | 2000-09-06 | 2006-03-14 | Transnetyx, Inc. | Method for detecting a designated genetic sequence in murine genomic DNA |
US20050239125A1 (en) * | 2000-09-06 | 2005-10-27 | Hodge Timothy A | Methods for genotype screening |
JP2004508057A (en) * | 2000-09-06 | 2004-03-18 | ホッジ ティモシー エイ | System, method and apparatus for screening for transgenic and target specific mutations |
EP1349951A4 (en) * | 2001-01-09 | 2005-08-24 | Whitehead Biomedical Inst | Methods and reagents for the isolation of nucleic acids |
US6692700B2 (en) | 2001-02-14 | 2004-02-17 | Handylab, Inc. | Heat-reduction methods and systems related to microfluidic devices |
US8895311B1 (en) | 2001-03-28 | 2014-11-25 | Handylab, Inc. | Methods and systems for control of general purpose microfluidic devices |
US7829025B2 (en) | 2001-03-28 | 2010-11-09 | Venture Lending & Leasing Iv, Inc. | Systems and methods for thermal actuation of microfluidic devices |
JPWO2003006650A1 (en) * | 2001-07-09 | 2004-11-04 | 旭化成株式会社 | Nucleic acid purification method and detection method using nonwoven fabric |
US7148343B2 (en) | 2001-10-12 | 2006-12-12 | Gentra Systems, Inc. | Compositions and methods for using a solid support to purify RNA |
US7893228B2 (en) | 2001-10-12 | 2011-02-22 | Qiagen North American Holdings, Inc. | Compositions and methods for using a solid support to purify RNA |
US20050032105A1 (en) | 2001-10-12 | 2005-02-10 | Bair Robert Jackson | Compositions and methods for using a solid support to purify DNA |
KR100445560B1 (en) * | 2001-10-31 | 2004-08-21 | (주)바이오넥스 | Method of manufacturing kit for isolating nucleic acids or biological materials, kit manufactured by the method, and apparatus using the kit |
DE60234464D1 (en) * | 2001-11-28 | 2009-12-31 | Applied Biosystems Llc | Compositions and methods for selective nucleic acid isolation |
JP4148900B2 (en) | 2002-01-08 | 2008-09-10 | エフ.ホフマン−ラ ロシュ アーゲー | Use of silica materials in amplification reactions |
US7786295B2 (en) | 2002-02-15 | 2010-08-31 | Qiegen North American Holdings, Inc | Method to isolate DNA |
GB0212826D0 (en) | 2002-05-31 | 2002-07-10 | Dna Res Innovations Ltd | Materials and methods relating to polyions and substance delivery |
GB0215185D0 (en) | 2002-07-01 | 2002-08-07 | Genovision As | Binding a target substance |
EP1388588B1 (en) * | 2002-07-29 | 2008-09-17 | JSR Corporation | Nucleic acid-separating method and nucleic acid-extracting reagent |
ATE420166T1 (en) † | 2002-10-04 | 2009-01-15 | Whatman Inc | METHOD AND MATERIALS FOR USING CHEMICAL COMPOUNDS AS AIDS FOR NUCLEIC ACID STORAGE ON MEDIA OF NUCLEIC ACID PURIFICATION SYSTEMS |
US20040180445A1 (en) * | 2003-03-12 | 2004-09-16 | Domanico Michael J. | Methods and compositions for purification of nucleic acid from a host cell |
WO2004108925A1 (en) * | 2003-06-04 | 2004-12-16 | Qiagen As | Method for sequentially isolating dna and rna from the same nucleic acid-containing sample |
CN1882688B (en) † | 2003-07-25 | 2014-07-16 | 安比恩股份有限公司 | Methods and compositions for isolating small RNA molecules |
EP1654066B1 (en) | 2003-07-31 | 2014-11-12 | Handylab, Inc. | Processing particle-containing samples |
US8470586B2 (en) * | 2004-05-03 | 2013-06-25 | Handylab, Inc. | Processing polynucleotide-containing samples |
US8852862B2 (en) | 2004-05-03 | 2014-10-07 | Handylab, Inc. | Method for processing polynucleotide-containing samples |
AU2005323451B2 (en) * | 2004-05-21 | 2010-11-18 | Qiagen Sciences Llc | Kits and processes for removing contaminants from nucleic acids in environmental and biological samples |
US20060024712A1 (en) * | 2004-06-25 | 2006-02-02 | Invitrogen Corporation | Separation of nucleic acid |
JP2008510456A (en) | 2004-07-30 | 2008-04-10 | アジェンコート バイオサイエンス コーポレーション | Nucleic acid isolation method using polyfunctional group-coated solid support |
CA2586532C (en) | 2004-11-05 | 2014-03-25 | Qiagen North American Holdings, Inc. | Compositions and methods for purifying nucleic acids from stabilization reagents |
US20060166223A1 (en) * | 2005-01-26 | 2006-07-27 | Reed Michael W | DNA purification and analysis on nanoengineered surfaces |
WO2006088907A2 (en) | 2005-02-15 | 2006-08-24 | University Of Virginia Patent Foundation | Nucleic acid isolation methods and materials and devices thereof |
US7794659B2 (en) * | 2005-03-10 | 2010-09-14 | Gen-Probe Incorporated | Signal measuring system having a movable signal measuring device |
WO2006136314A1 (en) | 2005-06-23 | 2006-12-28 | Siemens Medical Solutions Diagnostics Gmbh | Magnetic particles with a closed ultrathin silica layer, method for the production thereof and their use |
DE102005047736B4 (en) * | 2005-09-29 | 2008-08-14 | Aj Innuscreen Gmbh | Method and system for isolating nucleic acids from any complex starting materials |
US8883490B2 (en) | 2006-03-24 | 2014-11-11 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US10900066B2 (en) | 2006-03-24 | 2021-01-26 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
DK2001990T3 (en) | 2006-03-24 | 2016-10-03 | Handylab Inc | Integrated microfluidic sample processing system and method for its use |
US7998708B2 (en) | 2006-03-24 | 2011-08-16 | Handylab, Inc. | Microfluidic system for amplifying and detecting polynucleotides in parallel |
US11806718B2 (en) | 2006-03-24 | 2023-11-07 | Handylab, Inc. | Fluorescence detector for microfluidic diagnostic system |
US20100216657A1 (en) * | 2006-05-16 | 2010-08-26 | Arcxis Biotechnologies, Inc. | Pcr-free sample preparation and detection systems for high speed biologic analysis and identification |
US8163535B2 (en) * | 2006-06-26 | 2012-04-24 | Blood Cell Storage, Inc. | Devices and processes for nucleic acid extraction |
US7608399B2 (en) * | 2006-06-26 | 2009-10-27 | Blood Cell Storage, Inc. | Device and method for extraction and analysis of nucleic acids from biological samples |
US20080003574A1 (en) * | 2006-06-28 | 2008-01-03 | Sigma-Aldrich Co. | Kits for RNA extraction |
US10131935B2 (en) | 2006-07-11 | 2018-11-20 | Aj Innuscreen Gmbh | Method for parallel isolation of viral nucleic acids |
DE102006032610C5 (en) * | 2006-07-11 | 2016-09-15 | Aj Innuscreen Gmbh | Method for the parallel isolation of viral nucleic acids |
CA3121745A1 (en) | 2006-11-06 | 2008-05-15 | Clondiag Gmbh | Assays using binding members and reported compounds |
WO2008061165A2 (en) * | 2006-11-14 | 2008-05-22 | Handylab, Inc. | Microfluidic cartridge and method of making same |
US20100190240A1 (en) * | 2007-03-21 | 2010-07-29 | Ibis Biosciences, Inc. | Reagents for nucleic acid purification |
CA2629589C (en) * | 2007-04-20 | 2016-03-29 | F.Hoffmann-La Roche Ag | Isolation and purification of nucleic acid molecules with a solid phase |
ES2665280T3 (en) | 2007-06-29 | 2018-04-25 | Becton, Dickinson And Company | Methods for the extraction and purification of components of biological samples |
US9186677B2 (en) | 2007-07-13 | 2015-11-17 | Handylab, Inc. | Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples |
WO2009012185A1 (en) | 2007-07-13 | 2009-01-22 | Handylab, Inc. | Polynucleotide capture materials, and methods of using same |
US8182763B2 (en) | 2007-07-13 | 2012-05-22 | Handylab, Inc. | Rack for sample tubes and reagent holders |
US9618139B2 (en) | 2007-07-13 | 2017-04-11 | Handylab, Inc. | Integrated heater and magnetic separator |
US8105783B2 (en) | 2007-07-13 | 2012-01-31 | Handylab, Inc. | Microfluidic cartridge |
US8287820B2 (en) | 2007-07-13 | 2012-10-16 | Handylab, Inc. | Automated pipetting apparatus having a combined liquid pump and pipette head system |
BRPI0814582B1 (en) | 2007-07-23 | 2021-05-11 | Clondiag Gmbh | method, and use of the total viral load in an untreated whole blood sample |
EP2191012A1 (en) * | 2007-09-21 | 2010-06-02 | Streck, Inc. | Nucleic acid isolation in preserved whole blood |
US8775092B2 (en) | 2007-11-21 | 2014-07-08 | Cosmosid, Inc. | Method and system for genome identification |
US8478544B2 (en) | 2007-11-21 | 2013-07-02 | Cosmosid Inc. | Direct identification and measurement of relative populations of microorganisms with direct DNA sequencing and probabilistic methods |
CN104531673B (en) | 2008-02-15 | 2018-03-16 | 生命科技公司 | Method and kit for DNA extractions |
DE102008010693A1 (en) | 2008-02-22 | 2009-08-27 | Qiagen Gmbh | New matrix materials, processes for their preparation and their use in methods of isolating biomolecules |
DE102008010692A1 (en) | 2008-02-22 | 2009-08-27 | Qiagen Gmbh | New matrices, processes for their preparation and their use in methods of isolating biomolecules |
DE102008029356A1 (en) * | 2008-06-20 | 2009-12-24 | Siemens Healthcare Diagnostics Gmbh | Process for the purification of nucleic acids, in particular from fixed tissue |
USD787087S1 (en) | 2008-07-14 | 2017-05-16 | Handylab, Inc. | Housing |
JP2012508015A (en) * | 2008-11-04 | 2012-04-05 | ブラッド・セル・ストレイジ,インコーポレイテッド | Nucleic acid extraction on curved glass surfaces |
JP5570422B2 (en) | 2009-01-16 | 2014-08-13 | アークレイ株式会社 | Nucleic acid sample production method and nucleic acid amplification product production method using the same |
US8790916B2 (en) | 2009-05-14 | 2014-07-29 | Genestream, Inc. | Microfluidic method and system for isolating particles from biological fluid |
CA2772020A1 (en) * | 2009-08-31 | 2011-03-03 | Mbio Diagnostics, Inc. | Integrated sample preparation and analyte detection |
US20110223588A1 (en) * | 2010-03-09 | 2011-09-15 | Biosample Llc | Solid Phase Nucleic Acid Extraction From Small Sample Volumes, and Release of Controlled Quantities |
DK2588609T3 (en) | 2010-06-29 | 2018-03-19 | Exscale Biospecimen Solutions Ab | METHOD AND KIT FOR SEQUENTIAL ISOLATION OF NUCLEOTIDE SPECIES FROM A SAMPLE |
US8747084B2 (en) | 2010-07-21 | 2014-06-10 | Aperia Technologies, Inc. | Peristaltic pump |
US20130261003A1 (en) | 2010-08-06 | 2013-10-03 | Ariosa Diagnostics, In. | Ligation-based detection of genetic variants |
US10167508B2 (en) | 2010-08-06 | 2019-01-01 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
US11031095B2 (en) | 2010-08-06 | 2021-06-08 | Ariosa Diagnostics, Inc. | Assay systems for determination of fetal copy number variation |
US20130040375A1 (en) | 2011-08-08 | 2013-02-14 | Tandem Diagnotics, Inc. | Assay systems for genetic analysis |
US11203786B2 (en) | 2010-08-06 | 2021-12-21 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20140342940A1 (en) | 2011-01-25 | 2014-11-20 | Ariosa Diagnostics, Inc. | Detection of Target Nucleic Acids using Hybridization |
US10533223B2 (en) | 2010-08-06 | 2020-01-14 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US8700338B2 (en) | 2011-01-25 | 2014-04-15 | Ariosa Diagnosis, Inc. | Risk calculation for evaluation of fetal aneuploidy |
GB201020095D0 (en) | 2010-11-26 | 2011-01-12 | Invitrogen Dynal As | Nucleic acid preparation method |
CN103403187A (en) * | 2011-01-18 | 2013-11-20 | 艾沃锐斯特基因有限公司 | Prognostic signature for colorectal cancer recurrence |
US8756020B2 (en) | 2011-01-25 | 2014-06-17 | Ariosa Diagnostics, Inc. | Enhanced risk probabilities using biomolecule estimations |
US9994897B2 (en) | 2013-03-08 | 2018-06-12 | Ariosa Diagnostics, Inc. | Non-invasive fetal sex determination |
US11270781B2 (en) | 2011-01-25 | 2022-03-08 | Ariosa Diagnostics, Inc. | Statistical analysis for non-invasive sex chromosome aneuploidy determination |
US10131947B2 (en) | 2011-01-25 | 2018-11-20 | Ariosa Diagnostics, Inc. | Noninvasive detection of fetal aneuploidy in egg donor pregnancies |
CA2833262C (en) | 2011-04-15 | 2020-08-18 | Becton, Dickinson And Company | Scanning real-time microfluidic thermocycler and methods for synchronized thermocycling and scanning optical detection |
US8629264B2 (en) | 2011-05-19 | 2014-01-14 | Blood Cell Storage, Inc. | Gravity flow fluidic device for nucleic acid extraction |
EP2546199A1 (en) | 2011-07-14 | 2013-01-16 | Université Catholique De Louvain | Solid iron oxide support for isolation of microorganisms |
JP5924888B2 (en) * | 2011-08-26 | 2016-05-25 | 関東化學株式会社 | Nucleic acid extraction method, nucleic acid extraction reagent kit, and nucleic acid extraction reagent |
US8712697B2 (en) | 2011-09-07 | 2014-04-29 | Ariosa Diagnostics, Inc. | Determination of copy number variations using binomial probability calculations |
EP2761305B1 (en) | 2011-09-30 | 2017-08-16 | Becton, Dickinson and Company | Unitized reagent strip |
USD692162S1 (en) | 2011-09-30 | 2013-10-22 | Becton, Dickinson And Company | Single piece reagent holder |
CN104023551A (en) * | 2011-11-04 | 2014-09-03 | 生物辐射实验室股份有限公司 | Simultaneous purification of cell components |
US9766207B2 (en) | 2011-11-04 | 2017-09-19 | Bio-Rad Laboratories, Inc. | Affinity methods and compositions employing electronic control of pH |
CN104040238B (en) | 2011-11-04 | 2017-06-27 | 汉迪拉布公司 | Polynucleotides sample preparation apparatus |
EP2794929B1 (en) * | 2011-12-21 | 2019-07-10 | Geneohm Sciences Canada Inc. | Enrichment and isolation of microbial cells and microbial nucleic acids from a biological sample |
AU2013214849B2 (en) | 2012-02-03 | 2016-09-01 | Becton, Dickinson And Company | External files for distribution of molecular diagnostic tests and determination of compatibility between tests |
CN104245745B (en) | 2012-02-09 | 2017-03-29 | 生命技术公司 | hydrophilic polymer particle and preparation method thereof |
JP6333737B2 (en) | 2012-02-09 | 2018-05-30 | ライフ テクノロジーズ コーポレーション | Conjugated polymer particles and method for producing the same |
CN104203964B (en) | 2012-02-09 | 2017-07-18 | 生命技术公司 | Hydrophobic diacrylamine compound |
WO2013123425A1 (en) | 2012-02-15 | 2013-08-22 | Bio-Rad Laboratories, Inc. | Electronic control of ph and ionic strength |
WO2013126620A1 (en) | 2012-02-23 | 2013-08-29 | Dow Agrosciences Llc | Automation of barrier-based plant nucleic acid and protein extraction |
US9222473B2 (en) | 2012-03-20 | 2015-12-29 | Aperia Technologies, Inc. | Passive pressure regulation mechanism |
US9321012B2 (en) | 2012-04-04 | 2016-04-26 | Bio-Rad Laboratories, Inc. | Electronic protein fractionation |
US10289800B2 (en) | 2012-05-21 | 2019-05-14 | Ariosa Diagnostics, Inc. | Processes for calculating phased fetal genomic sequences |
WO2014018195A1 (en) | 2012-06-21 | 2014-01-30 | Monsanto Technology Llc | Lysis buffer and methods for extraction of dna from plant material |
EP2875156A4 (en) | 2012-07-19 | 2016-02-24 | Ariosa Diagnostics Inc | Multiplexed sequential ligation-based detection of genetic variants |
CN103571824B (en) | 2012-08-09 | 2016-04-13 | 财团法人工业技术研究院 | Compositions and methods for isolating nucleic acids |
KR101365737B1 (en) | 2012-08-28 | 2014-02-20 | 한정헌 | Porous solid matter for rapid isolation of biological molecule for nucleic acid amplification reaction from biological sample and uses thereof |
GB201216387D0 (en) | 2012-09-13 | 2012-10-31 | Ge Healthcare Uk Ltd | Solid matrix for one step nucleic acid amplification |
US11453258B2 (en) | 2013-03-12 | 2022-09-27 | Aperia Technologies, Inc. | System for tire inflation |
US9604157B2 (en) | 2013-03-12 | 2017-03-28 | Aperia Technologies, Inc. | Pump with water management |
US10144254B2 (en) | 2013-03-12 | 2018-12-04 | Aperia Technologies, Inc. | Tire inflation system |
US10245908B2 (en) | 2016-09-06 | 2019-04-02 | Aperia Technologies, Inc. | System for tire inflation |
US10052428B2 (en) | 2013-03-15 | 2018-08-21 | Fenwal, Inc. | Methods and systems for the filterless reduction of leukocytes in a biological fluid |
EP3543362B1 (en) * | 2013-10-07 | 2021-09-08 | Mitsui Chemicals, Inc. | Pcr primer set for bacterial dna amplification, kit for detecting and/or identifying bacterial species, and method for detecting and/or identifying bacterial species |
EP3653723B1 (en) | 2014-02-10 | 2022-07-20 | Zymo Research Corporation | Methods for nucleic acid capture |
US20150252407A1 (en) * | 2014-03-09 | 2015-09-10 | Nvigen, Inc. | Nanostructure and methods of nucleic acid isolation |
SG11201609008PA (en) | 2014-04-29 | 2016-11-29 | Accudx Corp | A novel affinity matrix and devices for isolation and purification of rna and dna for point of care molecular devices |
US9879223B2 (en) | 2014-07-30 | 2018-01-30 | Fenwal, Inc. | Methods and systems for the reduction of leukocytes in a biological fluid |
JP6437250B2 (en) * | 2014-09-03 | 2018-12-12 | 株式会社ミズホメディー | Pretreatment method and nucleic acid extraction kit used therefor |
US10000750B2 (en) | 2014-10-09 | 2018-06-19 | Promega Corporation | Method of isolating nucleic acid |
EP3218480A1 (en) | 2014-11-14 | 2017-09-20 | Corning Incorporated | Methods and kits for post-ivt rna purification |
US11008604B2 (en) * | 2014-12-18 | 2021-05-18 | Global Life Sciences Solutions Operations UK Ltd | Analyte detection on a solid support by nucleic acid amplification coupled to an immunoassay |
GB201504459D0 (en) * | 2015-03-17 | 2015-04-29 | Moorlodge Biotech Ventures Ltd | Isolation of DNA |
US9422596B1 (en) | 2015-04-27 | 2016-08-23 | Norgen Biotek Corp. | Methods and columns for nucleic acid purification |
WO2017004556A1 (en) | 2015-07-02 | 2017-01-05 | Life Technologies Corporation | Polymer substrates formed from carboxy functional acrylamide |
WO2017004559A1 (en) | 2015-07-02 | 2017-01-05 | Life Technologies Corporation | Conjugation of carboxyl functional hydrophilic beads |
EP3320115B1 (en) | 2015-07-06 | 2020-09-02 | Life Technologies Corporation | Substrates and methods useful in sequencing |
WO2017040992A1 (en) | 2015-09-04 | 2017-03-09 | Mo Bio Laboratories, Inc. | Methods for co-isolation of nucelic acids and proteins |
JP2018526021A (en) * | 2015-09-11 | 2018-09-13 | コーニング インコーポレイテッド | Compositions and methods for purification of nucleic acids from blood samples |
US20180135040A1 (en) | 2016-02-16 | 2018-05-17 | Life Magnetics, Inc. | Methods for separating nucleic acids with graphene coated magnetic beads |
WO2017184984A1 (en) * | 2016-04-21 | 2017-10-26 | Cell Data Sciences, Inc. | Biomolecule processing from fixed biological samples |
WO2017192902A1 (en) * | 2016-05-04 | 2017-11-09 | Children's Hospital & Research Center At Oakland | Rapid extraction of nucleic acids from clinical samples for downstream applications |
DE102016121483B4 (en) | 2016-11-09 | 2020-06-18 | Axagarius Gmbh & Co. Kg | Particulate solid composite material for nucleic acid purification, containing magnetic nanoparticles, process for its production and its use |
US11129673B2 (en) | 2017-05-05 | 2021-09-28 | Uptake Medical Technology Inc. | Extra-airway vapor ablation for treating airway constriction in patients with asthma and COPD |
WO2019055926A2 (en) | 2017-09-18 | 2019-03-21 | Yin To Chiu | Method for using aqueous two-phase system for the isolation, purification and/or concentration of short nucleic acid fragments |
US11642920B2 (en) | 2018-11-27 | 2023-05-09 | Aperia Technologies, Inc. | Hub-integrated inflation system |
TWI733302B (en) * | 2020-01-09 | 2021-07-11 | 創想生物科技有限公司 | A method of isolating nucleic acids and the system thereof |
KR20220075978A (en) | 2020-11-30 | 2022-06-08 | (주)바이오니아 | Method of Separating Nucleic Acid by Using Binding Buffer with Chemicals Having Low-Mid Dielectric Constant |
CN112626174A (en) * | 2020-12-16 | 2021-04-09 | 广州源井生物科技有限公司 | Cell lysis solution and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5076950A (en) * | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
US5234824A (en) * | 1990-11-13 | 1993-08-10 | Specialty Laboratories, Inc. | Rapid purification of DNA |
US5705628A (en) * | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
Family Cites Families (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US873102A (en) | 1907-06-21 | 1907-12-10 | William W Sly | Clutch. |
SE328534B (en) | 1965-08-27 | 1970-09-21 | Astra Ab | |
US4055469A (en) | 1976-12-10 | 1977-10-25 | Eastman Kodak Company | Purification of microbial enzyme extracts using synthetic polyelectrolytes |
JPS598164B2 (en) | 1977-11-30 | 1984-02-23 | 三菱重工業株式会社 | Tanning equipment for filter materials such as dust masks |
AU530410B2 (en) | 1978-02-21 | 1983-07-14 | Sintef | Preparing aqueous emulsions |
JPS5940227B2 (en) | 1980-06-24 | 1984-09-28 | 富士通株式会社 | Reactive sputtering method |
DE3169833D1 (en) | 1980-08-22 | 1985-05-15 | Berthold Lab Prof R | Process for performing analytical determinations by means of the chemiluminescent method, and application of this process to immuno assays |
US4379843A (en) | 1981-01-26 | 1983-04-12 | Peter Cashion | Immobilization of polynucleotides and polypeptides with tritylated polysaccharides |
US5055556A (en) | 1981-10-06 | 1991-10-08 | The Board Of Trustees Of The Leland Stanford Jr. Univ. | Fluorescent conjugates for analysis of molecules and cells |
IL65131A0 (en) | 1982-02-28 | 1982-04-30 | Yeda Res & Dev | Process for the production of agarose-polyaldehyde beads and their biological applications |
NO155316C (en) | 1982-04-23 | 1987-03-11 | Sintef | PROCEDURE FOR MAKING MAGNETIC POLYMER PARTICLES. |
US4695537A (en) * | 1982-05-21 | 1987-09-22 | The University Of Tennessee Research Corp. | Particles sensitized with detergent-treated antigen for agglutination immunoassay |
GR79124B (en) | 1982-12-22 | 1984-10-02 | Genentech Inc | |
US4861705A (en) | 1983-01-31 | 1989-08-29 | Yeda Research And Development Company, Ltd. | Method for removing components of biological fluids |
DE3310337A1 (en) | 1983-03-22 | 1984-09-27 | Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg | METHOD FOR CARRYING OUT HYBRIDIZATION REACTIONS |
US4672040A (en) | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
US4648975A (en) | 1983-08-17 | 1987-03-10 | Pedro B. Macedo | Process of using improved silica-based chromatographic supports containing additives |
US4920061A (en) | 1984-03-02 | 1990-04-24 | The University Of Texas System | Biological magnetic colloids |
US4652517A (en) | 1984-06-11 | 1987-03-24 | Diagnostic Research Limited Partnership | Methods for the in vitro detection and identification of unknown pathogens or genetic entities |
AU571979B2 (en) | 1984-07-06 | 1988-04-28 | Ciba-Geigy Ag | Ionically modified polysaccharides |
GB8501671D0 (en) | 1985-01-23 | 1985-02-27 | Allen G J | Immunoassay |
GB8507706D0 (en) | 1985-03-25 | 1985-05-01 | Genetics Int Inc | Magnetic nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4897444A (en) | 1985-05-31 | 1990-01-30 | The Research Foundation Of The State University Of New York | Immobilized fluorogenic substrates for enzymes; and processes for their preparation |
US4710472A (en) | 1985-09-25 | 1987-12-01 | The United States Of America As Represented By The Secretary Of The Navy | Magnetic separation device |
US4889916A (en) | 1985-11-19 | 1989-12-26 | The Johns Hopkins University | Protein label and drug delivery system |
US4772550A (en) | 1986-02-10 | 1988-09-20 | Miles Inc. | Heterogeneous specific binding assay employing an aggregatable binding reagent |
US4871433A (en) | 1986-04-04 | 1989-10-03 | Materials Research Corporation | Method and apparatus for improving the uniformity ion bombardment in a magnetron sputtering system |
US6881536B1 (en) | 1986-04-30 | 2005-04-19 | Bioveris Corporation | Particle based electrochemiluminescent assays |
FR2600655B1 (en) | 1986-06-30 | 1988-10-21 | Centre Nat Rech Scient | PROTEIN FRACTION EXTRACTED FROM GROWTH FACTOR ACTIVITIES, OBTAINING AND APPLICATION AS A STIMULATION AND POTENTIALIZING AGENT FOR GROWTH FACTOR ACTIVITIES |
US4843012A (en) | 1986-09-17 | 1989-06-27 | Genetics Institute, Inc. | Novel composition for nucleic acid purification |
DE3639949A1 (en) | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | METHOD FOR SEPARATING LONG CHAIN NUCLEIC ACIDS |
US4935342A (en) | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
US4767670A (en) | 1987-01-21 | 1988-08-30 | E. I. Du Pont De Nemours And Company | Chromatographic supports for separation of oligonucleotides |
US4874813A (en) | 1987-02-09 | 1989-10-17 | Shannessy Daniel J O | Proteins bound to a marker or solid phase support matrix using a hydrazone linkage |
NO162946C (en) | 1987-08-21 | 1990-03-14 | Otto Soerensen | DEVICE FOR MAGNETIC SEPARATION OF CELLS. |
US5599667A (en) | 1987-03-02 | 1997-02-04 | Gen-Probe Incorporated | Polycationic supports and nucleic acid purification separation and hybridization |
PT86881A (en) | 1987-03-02 | 1989-03-30 | Lyle J Arnold Jr | METHOD FOR THE PURIFICATION, SEPARATION AND HYBRIDACAO OF NUCLEIC ACIDS USING POLYCYTATIC SUPPORTS |
US5079155A (en) | 1987-03-02 | 1992-01-07 | E. I. Du Pont De Nemours And Company | Fluorocarbon polymer support for chromatographic separations, diagnostic assays and enzyme immobilization |
DE3717211A1 (en) | 1987-05-22 | 1988-12-01 | Diagen Inst Molekularbio | DEVICE AND METHOD FOR SEPARATING AND CLEANING MOLECULES |
CA1297432C (en) | 1987-07-29 | 1992-03-17 | Gulilat Gebeyehu | Nucleic acid capture reagent |
US4921805A (en) | 1987-07-29 | 1990-05-01 | Life Technologies, Inc. | Nucleic acid capture method |
FR2619568B1 (en) | 1987-08-21 | 1989-07-07 | Centre Nat Rech Scient | POLYSTYRENE-DERIVED POLYMERS, PROCESSES FOR THE PREPARATION THEREOF AND APPLICATIONS THEREOF FOR THE ANALYSIS AND PURIFICATION OF ORGANIC MOLECULES |
US4908318A (en) | 1987-09-04 | 1990-03-13 | Integrated Genetics, Inc. | Nucleic acid extraction methods |
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
US4923978A (en) | 1987-12-28 | 1990-05-08 | E. I. Du Pont De Nemours & Company | Process for purifying nucleic acids |
GB8800702D0 (en) | 1988-01-13 | 1988-02-10 | Nycomed As | Test method & reagent kit therefor |
US5183809A (en) | 1990-02-15 | 1993-02-02 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Cyclodextrin polymers and cyclodextrins immobilized on a solid surface |
US4875045A (en) | 1988-03-09 | 1989-10-17 | Northern Telecom Limited | Variable gain encoder apparatus and method |
JP2791367B2 (en) | 1988-04-21 | 1998-08-27 | マイクロプローブ・コーポレーション | Nucleic acid extraction method |
US4952519A (en) | 1988-05-02 | 1990-08-28 | E. I. Du Pont De Nemours And Company | Protein immobilization with poly(ethyleneimine) derivatized with a hydroprobic group |
DE3921498A1 (en) | 1988-09-28 | 1990-03-29 | Bayer Ag | POLYMER-TIED DYES, METHOD FOR THE PRODUCTION AND USE THEREOF |
US5807527A (en) | 1991-05-29 | 1998-09-15 | Flinders Technologies Pty. Ltd. | Solid medium and method for DNA storage |
CA1335181C (en) | 1988-10-11 | 1995-04-11 | R. Alan Hardwick | System for selective cell separation from cell concentrate |
IE883226L (en) | 1988-10-25 | 1990-04-25 | Dna Prep Galway Ltd S 22 | Separation of nucleic acids from protein material using¹cation exchangers |
US5028696A (en) | 1988-10-28 | 1991-07-02 | Torres Anthony R | Ion exchange and separation method |
US6448091B1 (en) | 1988-11-03 | 2002-09-10 | Igen International, Inc. | Method and apparatus for improved luminescence assays using particle concentration chemiluminescence detection |
GB8827160D0 (en) | 1988-11-21 | 1988-12-29 | Apothekernes Lab | Detection & quantitative determination of rna & dna |
US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
GR1000347B (en) | 1988-12-21 | 1992-06-25 | Ortho Diagnostic Systems Inc | Method of preparing nucleotide probes using a bridging complement |
AU5040590A (en) | 1989-01-23 | 1990-08-13 | Invitron Corporation | Method for removing dna from protein preparations |
JP2910929B2 (en) | 1989-03-23 | 1999-06-23 | 浜松ホトニクス株式会社 | Surface modification method for particles composed of magnetic particles |
NL8900725A (en) | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | METHOD AND COMBINATION OF AGENTS FOR INSULATING NUCLEIC ACID. |
US5234809A (en) | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US4957605A (en) | 1989-04-17 | 1990-09-18 | Materials Research Corporation | Method and apparatus for sputter coating stepped wafers |
US5334499A (en) | 1989-04-17 | 1994-08-02 | Eastman Kodak Company | Methods of extracting, amplifying and detecting a nucleic acid from whole blood or PBMC fraction |
US5126028A (en) | 1989-04-17 | 1992-06-30 | Materials Research Corporation | Sputter coating process control method and apparatus |
US6010867A (en) | 1989-04-19 | 2000-01-04 | Ibiden Co., Ltd. | Reagent for biomaterials assay, preparation method thereof, and assay method |
DE3916595A1 (en) | 1989-05-22 | 1990-11-29 | Boehringer Mannheim Gmbh | METHOD FOR NON-RADIOACTIVE MEASURING OF NUCLEIC ACID SYNTHESIS IN EUKARYONTIC CELLS |
NO168811C (en) | 1989-05-31 | 1992-04-08 | Dynal As | Separation device for separating magnetizable particles |
US5124444A (en) | 1989-07-24 | 1992-06-23 | Microprobe Corporation | Lactam-containing compositions and methods useful for the extraction of nucleic acids |
ATE103507T1 (en) | 1989-08-07 | 1994-04-15 | Baker J T Inc | SOLID CARRIER OF QUATERMIZED PEI SILICA FOR CHROMATOGRAPHY. |
US5032281A (en) | 1989-08-09 | 1991-07-16 | Daicel Chemical Industries, Ltd. | Separating membrane and separation method |
US5128247A (en) | 1989-08-14 | 1992-07-07 | Board Of Regents, The University Of Texas System | Methods for isolation of nucleic acids from eukaryotic and prokaryotic sources |
US5084169A (en) | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
US5433847A (en) | 1989-11-01 | 1995-07-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Radial flow chromatography |
US5641628A (en) | 1989-11-13 | 1997-06-24 | Children's Medical Center Corporation | Non-invasive method for isolation and detection of fetal DNA |
US4997932A (en) | 1989-11-13 | 1991-03-05 | Boehringer Mannheim Corporation | Method and kit for purifying nucleic acids |
DE69031984T2 (en) | 1989-11-13 | 1998-09-10 | Childrens Medical Center | A NON-INVASIVE METHOD FOR SEPARATING AND DETECTING FETAL DNA |
US5000635A (en) | 1989-11-17 | 1991-03-19 | The Boeing Company | Spring-loaded outboard side lock |
WO1991008308A1 (en) | 1989-11-30 | 1991-06-13 | Pharmacia Genetic Engineering, Inc. | A new method for detecting a specific nucleic acid sequence in a sample of cells |
GB9003253D0 (en) | 1990-02-13 | 1990-04-11 | Amersham Int Plc | Precipitating polymers |
US5523231A (en) | 1990-02-13 | 1996-06-04 | Amersham International Plc | Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules |
IT1240870B (en) | 1990-02-14 | 1993-12-17 | Talent | PROCEDURE FOR THE EXTRACTION AND PURIFICATION OF HUMAN GENOMIC DNA |
CA2082936C (en) | 1990-05-15 | 2003-09-23 | Peter O. G. Arrhenius | Fluorescent porphyrin, and fluorescent phthalocyanine-polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes |
US5234924A (en) | 1990-09-26 | 1993-08-10 | Adir Et Compagnie | Benzothiazine and benzothiazole compounds useful as analgesics |
DE4034036C2 (en) | 1990-10-26 | 1994-03-03 | Diagen Inst Molekularbio | Device and method for isolating nucleic acids from cell suspensions |
WO1992008133A1 (en) | 1990-10-29 | 1992-05-14 | Dekalb Plant Genetics | Isolation of biological materials using magnetic particles |
US5654179A (en) | 1990-11-14 | 1997-08-05 | Hri Research, Inc. | Nucleic acid preparation methods |
DE4038293A1 (en) | 1990-11-28 | 1992-06-04 | Inst Molekularbiologie Ak | Nucleic acid adduct for in situ hybridisation to give nucleic acid sequences - comprises water soluble basic polymer and nucleic acid sequence formed by polymerase chain reaction and/or reverse transcriptase reaction |
US5204246A (en) | 1990-12-26 | 1993-04-20 | Pioneer Hi-Bred International, Inc. | Dna isolation method |
US5296347A (en) | 1991-02-08 | 1994-03-22 | Ciba Corning Diagnostics Corp. | Bridge immunoassay |
US5491223A (en) | 1991-02-28 | 1996-02-13 | Daicel Chemical Industries, Ltd. | Polysaccharide derivative and separating agent |
GB9107124D0 (en) | 1991-04-05 | 1991-05-22 | Dynal As | Chemical process |
CA2067711C (en) | 1991-05-03 | 2000-08-08 | Daniel Lee Woodard | Solid phase extraction purification of dna |
US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
US5155018A (en) | 1991-07-10 | 1992-10-13 | Hahnemann University | Process and kit for isolating and purifying RNA from biological sources |
FR2679255B1 (en) | 1991-07-17 | 1993-10-22 | Bio Merieux | METHOD OF IMMOBILIZING A NUCLEIC FRAGMENT BY PASSIVE FIXING ON A SOLID SUPPORT, SOLID SUPPORT THUS OBTAINED AND ITS USE. |
WO1993003167A1 (en) | 1991-08-06 | 1993-02-18 | The World Health Organisation | Method of isolation of dna |
US5329000A (en) | 1991-10-31 | 1994-07-12 | Becton, Dickinson And Company | Purification of DNA with silicon tetrahydrazide |
US6051380A (en) | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
DE69324716T2 (en) | 1992-02-13 | 1999-09-09 | Becton Dickinson Co | Celite hydrate and purification of DNA |
DE4208645A1 (en) | 1992-03-18 | 1993-09-23 | Bayer Ag | OPTICAL SOLID PHASE BIOSENSOR BASED ON FLUORESCENT COLOR-MARGINED POLYIONIC LAYERS |
DE4237381C1 (en) | 1992-11-05 | 1994-04-28 | Diagen Inst Molekularbio | Carrier material for the simultaneous binding of genotypic and phenotypic substances |
GB9212164D0 (en) * | 1992-06-09 | 1992-07-22 | Medical Res Council | Preparation of nucleic acids |
US5710028A (en) | 1992-07-02 | 1998-01-20 | Eyal; Nurit | Method of quick screening and identification of specific DNA sequences by single nucleotide primer extension and kits therefor |
GB9220773D0 (en) | 1992-10-02 | 1992-11-18 | Mini Agriculture & Fisheries | Detection of antigens and nucleic acids |
GB2272391A (en) | 1992-11-05 | 1994-05-18 | Gordon Henry Turner | Drilling jig |
GB9223334D0 (en) | 1992-11-06 | 1992-12-23 | Hybaid Ltd | Magnetic solid phase supports |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
DE69428891T2 (en) | 1993-03-29 | 2002-06-27 | Minnesota Mining & Mfg | METHOD FOR CONNECTING LIGANDS IN A POROUS CARRIER (e.g. AZLAKTON) AND ITS APPLICATIONS |
US5503816A (en) | 1993-09-27 | 1996-04-02 | Becton Dickinson And Company | Silicate compounds for DNA purification |
US5438129A (en) | 1993-09-27 | 1995-08-01 | Becton Dickinson And Company | DNA purification by solid phase extraction using partially fluorinated aluminum hydroxide adsorbant |
GB2282138B (en) | 1993-09-28 | 1997-09-03 | Tosoh Corp | Method of extracting nucleic acids and method of detecting specified nucleic acid sequences |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US20030044777A1 (en) | 1993-10-28 | 2003-03-06 | Kenneth L. Beattie | Flowthrough devices for multiple discrete binding reactions |
GB9323305D0 (en) | 1993-11-11 | 1994-01-05 | Medinnova Sf | Isoaltion of nucleic acid |
DE4432654C2 (en) | 1994-09-14 | 1998-03-26 | Qiagen Gmbh | Process for the isolation of nucleic acids from natural sources |
WO1995027718A2 (en) | 1994-04-08 | 1995-10-19 | Hybridon, Inc. | Purification of oligodeoxynucleotide phosphorothioates using anion exchange chromatography |
WO1996000228A1 (en) | 1994-06-23 | 1996-01-04 | Dade International Inc. | Method for the rapid isolation of nucleic acid |
EP0777032A4 (en) | 1994-08-25 | 1999-12-22 | Iseki Kaihatsu Koki | Excavator for vertical bores |
US5622822A (en) | 1994-09-13 | 1997-04-22 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using polyethyleneimine and an anionic phosphate ester surfactant and amplification of same |
US5582988A (en) | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
US5652348A (en) | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
US5660984A (en) | 1994-12-09 | 1997-08-26 | Davis; Thomas E. | DNA isolating apparatus comprising a non-porous DNA binding, anion exchange resin and methods of use thereof |
GB9425138D0 (en) | 1994-12-12 | 1995-02-08 | Dynal As | Isolation of nucleic acid |
US5631146A (en) | 1995-01-19 | 1997-05-20 | The General Hospital Corporation | DNA aptamers and catalysts that bind adenosine or adenosine-5'-phosphates and methods for isolation thereof |
US5762903A (en) | 1995-03-10 | 1998-06-09 | Korea Atomic Energy Research Institute | Radioactive chitosan complex for radiation therapy |
ES2164241T3 (en) | 1995-04-28 | 2002-02-16 | Daiichi Seiyaku Co | PENTACICLIC COMPOUNDS. |
US5702147A (en) * | 1995-05-09 | 1997-12-30 | Bestop, Inc. | Tailgate sealing arrangement |
AR003122A1 (en) | 1995-05-19 | 1998-07-08 | Merck & Co Inc | A PROCESS FOR ISOLATION AND PURIFICATION OF PLASMIDS IN LARGE SCALE FERMENTATORS AND ISOLATED AND PURIFIED DNA OBTAINED THROUGH SUCH A PROCESS. |
DE19520398B4 (en) | 1995-06-08 | 2009-04-16 | Roche Diagnostics Gmbh | Magnetic pigment |
WO1996041810A1 (en) | 1995-06-08 | 1996-12-27 | Progen Industries Limited | Method and apparatus for dna extraction |
JP2965131B2 (en) | 1995-07-07 | 1999-10-18 | 東洋紡績株式会社 | Magnetic carrier for nucleic acid binding and nucleic acid isolation method using the same |
JP3872513B2 (en) | 1995-08-28 | 2007-01-24 | アドバンスト ナノ テクノロジィーズ プロプライエタリ リミテッド | Manufacturing method of ultrafine particles |
US5783686A (en) | 1995-09-15 | 1998-07-21 | Beckman Instruments, Inc. | Method for purifying nucleic acids from heterogenous mixtures |
US6677164B1 (en) | 1995-11-21 | 2004-01-13 | Novartis Ag | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds |
US5612473A (en) | 1996-01-16 | 1997-03-18 | Gull Laboratories | Methods, kits and solutions for preparing sample material for nucleic acid amplification |
US6803188B1 (en) | 1996-01-31 | 2004-10-12 | The Regents Of The University Of California | Tandem fluorescent protein constructs |
US5981735A (en) | 1996-02-12 | 1999-11-09 | Cobra Therapeutics Limited | Method of plasmid DNA production and purification |
SE9600590D0 (en) | 1996-02-19 | 1996-02-19 | Pharmacia Biotech Ab | Methods for chromatographic separation of peptides and nucleic acid and new high-affinity ion exchange matrix |
DE69738791D1 (en) | 1996-02-25 | 2008-08-07 | Prec System Science Co Ltd | METHOD FOR THE TREATMENT OF BIOPOLYMERS, MICRO-ORGANISMS OR OTHER MATERIALS USING MORE THAN ONE TYPE OF MAGNETIC PARTICLES. |
NO961221D0 (en) | 1996-03-26 | 1996-03-26 | Oeystein Fodstad | Method of identifying new genes associated with site-preferential cancer metastasis formation |
SE9601318D0 (en) | 1996-04-04 | 1996-04-04 | Pharmacia Biosensor Ab | Method for nucleic acid analysis |
US5780319A (en) | 1996-04-19 | 1998-07-14 | Pasteur Sanofi Diagnostics | Immunoassays to detect antiphospholipid antibodies |
US5916746A (en) | 1996-05-09 | 1999-06-29 | Kirkegaard & Perry Laboratories, Inc. | Formazan-based immunoassay |
US5962412A (en) | 1996-06-10 | 1999-10-05 | Arqule, Inc. | Method of making polymers having specific properties |
US5981235A (en) | 1996-07-29 | 1999-11-09 | Promega Corporation | Methods for isolating nucleic acids using alkaline protease |
JP3793287B2 (en) | 1996-08-22 | 2006-07-05 | ペンタックス株式会社 | Method for isolating plasmid DNA |
CA2214495C (en) | 1996-09-25 | 2002-02-05 | Daniel L. Woodard | Hydrated zirconium silicate composition for purification of nucleic acids |
US5795748A (en) | 1996-09-26 | 1998-08-18 | Becton Dickinson And Company | DNA microwell device and method |
EP0938549A1 (en) | 1996-10-10 | 1999-09-01 | Biotechnology Research And Development Corporation | Polymer-protein composites and methods for their preparation and use |
CA2268740C (en) | 1996-11-06 | 2010-07-20 | Sequenom, Inc. | High density immobilization of nucleic acids |
US6060246A (en) | 1996-11-15 | 2000-05-09 | Avi Biopharma, Inc. | Reagent and method for isolation and detection of selected nucleic acid sequences |
EP0853123A1 (en) | 1997-01-10 | 1998-07-15 | Roche Diagnostics GmbH | Purification of DNA by 'cross-flow-filtration' |
US6027945A (en) | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
US5770712A (en) | 1997-03-14 | 1998-06-23 | Virginia Tech Intellectual Properties, Inc. | Crosslinked hydrogel beads from chitosan |
GB9709728D0 (en) * | 1997-05-13 | 1997-07-02 | Dynal As | Single step method |
US20040152084A1 (en) | 2003-01-31 | 2004-08-05 | Slattum Paul M. | Compounds and processes for single-pot attachment of a label to nucleic acid |
US5958788A (en) | 1997-05-28 | 1999-09-28 | Nalco Chemical Company | Luminol tagged polymers for treatment of industrial systems |
CA2293820A1 (en) | 1997-06-25 | 1998-12-30 | Promega Corporation | Method of isolating rna |
EP0897978A3 (en) | 1997-08-22 | 2001-10-17 | Becton, Dickinson and Company | Zirconium oxide and related compounds for purification of nucleic acids |
DE19739218A1 (en) | 1997-09-08 | 1999-03-11 | Boehringer Mannheim Gmbh | Purification of substances from a biological sample |
JP4304348B2 (en) | 1997-09-22 | 2009-07-29 | 独立行政法人理化学研究所 | DNA isolation method |
DE19746874A1 (en) | 1997-10-23 | 1999-04-29 | Qiagen Gmbh | Isolation of nucleic acids |
AU9527098A (en) | 1997-10-23 | 1999-05-17 | Nicholas A. D. Burke | Labelling of polymers and sequencing of nucleic acids |
DE19747572C1 (en) | 1997-10-28 | 1999-04-08 | Inst Chemo Biosensorik | Apparatus for fluorescence immunoassay |
US6120985A (en) | 1997-10-31 | 2000-09-19 | Bbi Bioseq, Inc. | Pressure-enhanced extraction and purification |
GB9725197D0 (en) | 1997-11-29 | 1998-01-28 | Secr Defence | Detection system |
WO1999029703A2 (en) | 1997-12-06 | 1999-06-17 | Dna Research Instruments Limited | Isolation of nucleic acids |
US6914137B2 (en) | 1997-12-06 | 2005-07-05 | Dna Research Innovations Limited | Isolation of nucleic acids |
DE69941689D1 (en) | 1998-02-12 | 2010-01-07 | Univ Texas | METHOD AND REAGENTS FOR RAPID AND EFFICIENT INSULATION OF CIRCULATING CANCER CELLS |
FR2777355B1 (en) | 1998-04-10 | 2000-05-12 | Bio Merieux | PROCESS FOR FIXING A BIOLOGICAL MOLECULE ON THE SURFACE OF A SUPPORT CONSISTING OF SILICA OR METAL OXIDE |
US6194562B1 (en) | 1998-04-22 | 2001-02-27 | Promega Corporation | Endotoxin reduction in nucleic acid purification |
US7078224B1 (en) | 1999-05-14 | 2006-07-18 | Promega Corporation | Cell concentration and lysate clearance using paramagnetic particles |
US6287772B1 (en) | 1998-04-29 | 2001-09-11 | Boston Probes, Inc. | Methods, kits and compositions for detecting and quantitating target sequences |
US6534262B1 (en) | 1998-05-14 | 2003-03-18 | Whitehead Institute For Biomedical Research | Solid phase technique for selectively isolating nucleic acids |
US6287765B1 (en) | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
US6245507B1 (en) | 1998-08-18 | 2001-06-12 | Orchid Biosciences, Inc. | In-line complete hyperspectral fluorescent imaging of nucleic acid molecules |
WO2000029848A1 (en) | 1998-11-17 | 2000-05-25 | Proteo Tools | Separation, screening, and identification of biological targets |
DE69929826D1 (en) | 1998-11-23 | 2006-04-20 | Us Gov Sec Army | CLEANING METHOD AND DEVICE |
FI990082A0 (en) | 1999-01-18 | 1999-01-18 | Labsystems Oy | Purification process using magnetic particles |
AU2862100A (en) | 1999-01-27 | 2000-08-18 | Folim G. Halaka | Materials and methods for the purification of polyelectrolytes |
EP1153049B1 (en) | 1999-01-29 | 2005-08-10 | Amersham Biosciences KK | Temperature-responsive polymer compound and process for producing the same |
DE19907023A1 (en) | 1999-02-19 | 2000-08-24 | Bayer Ag | Isolation of nucleic acids, useful for e.g. genetic diagnosis by amplification, by adsorption onto polymeric beads at neutral or acidic pH then release at basic pH |
GB9907245D0 (en) | 1999-03-29 | 1999-05-26 | Goldsborough Andrew | Cleavage of nucleic acids from solid supports |
AU4058100A (en) | 1999-04-09 | 2000-11-14 | Arcturus Engineering, Inc. | Generic cdna or protein array for customized assays |
CA2270106C (en) | 1999-04-23 | 2006-03-14 | Yousef Haj-Ahmad | Nucleic acid purification and process |
US6270970B1 (en) | 1999-05-14 | 2001-08-07 | Promega Corporation | Mixed-bed solid phase and its use in the isolation of nucleic acids |
CA2372485A1 (en) | 1999-05-14 | 2000-11-23 | Rex M. Bitner | Cell concentration and lysate clearance using paramagnetic particles |
US6310199B1 (en) | 1999-05-14 | 2001-10-30 | Promega Corporation | pH dependent ion exchange matrix and method of use in the isolation of nucleic acids |
US6472141B2 (en) | 1999-05-21 | 2002-10-29 | Caliper Technologies Corp. | Kinase assays using polycations |
US6645733B1 (en) | 1999-06-25 | 2003-11-11 | Ingeneus Corporation | Fluorescent intensity method for assaying binding between proteins or peptides |
ES2258429T3 (en) | 1999-07-15 | 2006-09-01 | Qiagen Gmbh | METHODS TO SEPARATE SUBSTRATES IN PARTICLES OF A SOLUTION, AT THE TIME THAT THE LOSS OF PARTICLES IS MINIMIZED. |
WO2001038585A2 (en) | 1999-11-24 | 2001-05-31 | The Regents Of The University Of California | Polymer arrays and methods of using labeled probe molecules to identify and quantify target molecule expression |
US6582907B1 (en) | 1999-12-09 | 2003-06-24 | Pharmacia & Upjohn Company | Use of fluorescence correlation spectroscopy to identify compounds that bind to target species under isothermal denaturing conditions |
US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
US7078536B2 (en) | 2001-03-14 | 2006-07-18 | Genesoft Pharmaceuticals, Inc. | Charged compounds comprising a nucleic acid binding moiety and uses therefor |
US6489160B2 (en) | 2000-03-16 | 2002-12-03 | Kabushiki Kaisha Toshiba | Method for producing nucleic acid strand immobilized carrier |
US7262006B1 (en) | 2000-05-01 | 2007-08-28 | Ortho-Clinical Diagnostics, Inc. | Rapid and efficient capture of DNA from sample without using cell lysing reagent |
GB0013658D0 (en) | 2000-06-05 | 2000-07-26 | Dynal Asa | Nucleic acid isolation |
US7501284B2 (en) | 2000-07-31 | 2009-03-10 | Applera Corporation | Apparatus and method for specific release of captured extension products |
WO2002016580A2 (en) | 2000-08-24 | 2002-02-28 | Bio-Rad Laboratories, Inc. | Flow-through system for lysate clarification and nucleic acid binding in a single step |
US6627748B1 (en) | 2000-09-11 | 2003-09-30 | The Trustees Of Columbia University In The City Of New York | Combinatorial fluorescence energy transfer tags and their applications for multiplex genetic analyses |
GB0026560D0 (en) | 2000-10-30 | 2000-12-13 | Novartis Ag | Organic compounds |
DE60015360T9 (en) | 2000-11-20 | 2005-12-15 | Sony International (Europe) Gmbh | Method for the immobilization of nucleic acids on a solid support |
US6743586B2 (en) | 2001-01-29 | 2004-06-01 | The United States Of America As Represented By The Secretary Of The Commerce | Rapid fluorescence detection of binding to nucleic acid drug targets labelled with highly fluorescent nucleotide base analogs |
US7018610B2 (en) | 2001-03-02 | 2006-03-28 | University Of Western Ontario | Polymer precursors of radiolabeled compounds, and methods of making and using the same |
JP3975319B2 (en) | 2001-03-02 | 2007-09-12 | 富士ゼロックス株式会社 | Developing device and image forming apparatus using the same |
AU2002258997A1 (en) | 2001-04-24 | 2002-11-05 | Li-Cor, Inc. | Polymerases with charge-switch activity and methods of generating such polymerases |
US7338805B2 (en) | 2001-05-04 | 2008-03-04 | Bio Merieux | Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules |
US7183116B2 (en) | 2001-05-14 | 2007-02-27 | The Institute For Systems Biology | Methods for isolation and labeling of sample molecules |
WO2003017938A2 (en) | 2001-08-22 | 2003-03-06 | Watson Pharmaceuticals, Inc. | Conjugates targeted to target receptors |
US20030099954A1 (en) | 2001-11-26 | 2003-05-29 | Stefan Miltenyi | Apparatus and method for modification of magnetically immobilized biomolecules |
US20030229013A1 (en) | 2001-12-07 | 2003-12-11 | Shih-Kwang Wu | Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
JP3871677B2 (en) | 2001-12-27 | 2007-01-24 | 松下電器産業株式会社 | Immune reaction measurement method and immune reaction measurement reagent kit used therefor |
US20030147958A1 (en) | 2002-01-29 | 2003-08-07 | Cheol-Hee Ahn | Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents |
CA2480673A1 (en) | 2002-03-29 | 2003-10-09 | Genentech, Inc. | Methods and compositions for detection and quantitation of nucleic acid analytes |
GB0209539D0 (en) | 2002-04-26 | 2002-06-05 | Avecia Ltd | Monomer Polymer and process |
GB0212826D0 (en) | 2002-05-31 | 2002-07-10 | Dna Res Innovations Ltd | Materials and methods relating to polyions and substance delivery |
WO2004001379A2 (en) | 2002-06-20 | 2003-12-31 | The Regents Of The University Of California | Methods and compositions for detection and analysis of polynucleotides using light harvesting multichromophores |
ES2310197T3 (en) | 2002-10-18 | 2009-01-01 | Sloning Biotechnology Gmbh | METHOD FOR THE PREPARATION OF NUCLEIC ACID MOLECULES. |
FR2847581B1 (en) | 2002-11-21 | 2007-03-23 | Commissariat Energie Atomique | METHOD FOR FIXING A PROTEIN ON A POLYMER BASED ON PYRROLE AND ITS USE IN THE MANUFACTURE OF A SENSOR |
GB0229287D0 (en) | 2002-12-16 | 2003-01-22 | Dna Res Innovations Ltd | Polyfunctional reagents |
US20050123932A1 (en) | 2003-12-09 | 2005-06-09 | Mekbib Astatke | Nucleic acid-chelating agent conjugates |
BE1016163A6 (en) | 2004-08-18 | 2006-04-04 | Mc Anton Sa | METHOD Percutaneous HYPERBARIC OXYGEN SPRAY fluorocarbons. |
-
1994
- 1994-12-12 GB GBGB9425138.6A patent/GB9425138D0/en active Pending
-
1995
- 1995-12-12 DE DE69533317T patent/DE69533317T2/en not_active Expired - Lifetime
- 1995-12-12 AT AT95940351T patent/ATE272110T1/en active
- 1995-12-12 WO PCT/GB1995/002893 patent/WO1996018731A2/en active IP Right Grant
- 1995-12-12 EP EP95940351A patent/EP0796327B1/en not_active Revoked
- 1995-12-12 US US08/849,686 patent/US20040215011A1/en not_active Abandoned
- 1995-12-12 JP JP51846396A patent/JP3787354B2/en not_active Expired - Lifetime
- 1995-12-12 AU AU41829/96A patent/AU706211B2/en not_active Expired
- 1995-12-12 CA CA002207608A patent/CA2207608C/en not_active Expired - Fee Related
-
2005
- 2005-09-23 US US11/234,001 patent/US7173124B2/en not_active Expired - Fee Related
-
2007
- 2007-02-05 US US11/671,426 patent/US20070190559A1/en not_active Abandoned
-
2008
- 2008-03-24 US US12/054,332 patent/US7989614B2/en not_active Expired - Fee Related
- 2008-05-30 US US12/130,926 patent/US20090068724A1/en not_active Abandoned
- 2008-05-30 US US12/130,959 patent/US20090149646A1/en not_active Abandoned
-
2011
- 2011-06-14 US US13/160,428 patent/US8691969B2/en not_active Expired - Fee Related
-
2014
- 2014-02-19 US US14/183,999 patent/US20140291576A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5076950A (en) * | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
US5234824A (en) * | 1990-11-13 | 1993-08-10 | Specialty Laboratories, Inc. | Rapid purification of DNA |
US5705628A (en) * | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7989614B2 (en) | 1994-12-12 | 2011-08-02 | Invitrogen Dynal As | Isolation of nucleic acid |
US8691969B2 (en) | 1994-12-12 | 2014-04-08 | Life Technologies As | Isolation of nucleic acid |
US8110351B2 (en) | 2002-01-16 | 2012-02-07 | Invitrogen Dynal As | Method for isolating nucleic acids and protein from a single sample |
WO2009040444A1 (en) * | 2007-09-28 | 2009-04-02 | Mole Genetics As | Rna isolation method |
GB2466419A (en) * | 2007-09-28 | 2010-06-23 | Mole Genetics As | RNA isolation method |
GB2466419B (en) * | 2007-09-28 | 2011-04-13 | Mole Genetics As | RNA isolation method |
US20110104157A1 (en) * | 2008-04-04 | 2011-05-05 | Chugai Seiyaku Kabushiki Kaisha | Liver cancer drug |
Also Published As
Publication number | Publication date |
---|---|
US8691969B2 (en) | 2014-04-08 |
ATE272110T1 (en) | 2004-08-15 |
WO1996018731A2 (en) | 1996-06-20 |
US20090068724A1 (en) | 2009-03-12 |
US20090149646A1 (en) | 2009-06-11 |
US20140291576A1 (en) | 2014-10-02 |
US7173124B2 (en) | 2007-02-06 |
US20110251382A1 (en) | 2011-10-13 |
GB9425138D0 (en) | 1995-02-08 |
AU706211B2 (en) | 1999-06-10 |
US7989614B2 (en) | 2011-08-02 |
CA2207608A1 (en) | 1996-06-20 |
AU4182996A (en) | 1996-07-03 |
JP3787354B2 (en) | 2006-06-21 |
US20080300396A1 (en) | 2008-12-04 |
WO1996018731A3 (en) | 1996-09-12 |
EP0796327B1 (en) | 2004-07-28 |
CA2207608C (en) | 2009-04-07 |
DE69533317D1 (en) | 2004-09-02 |
US20040215011A1 (en) | 2004-10-28 |
JPH11501504A (en) | 1999-02-09 |
EP0796327A2 (en) | 1997-09-24 |
US20060058519A1 (en) | 2006-03-16 |
DE69533317T2 (en) | 2005-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7989614B2 (en) | Isolation of nucleic acid | |
US9464316B2 (en) | Method for isolating nucleic acids comprising the use of ethylene glycol multimers | |
AU751324C (en) | Solid-phase nucleic acid isolation | |
US8202693B2 (en) | Method of isolation of nucleic acids | |
US20070031880A1 (en) | Chemical treatment of biological samples for nucleic acid extraction and kits therefor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: INVITROGEN DYNAL AS, NORWAY Free format text: CHANGE OF NAME;ASSIGNORS:DNYAL AS;DYNAL ASA;DYNAL BIOTECH ASA;AND OTHERS;SIGNING DATES FROM 19990922 TO 20060322;REEL/FRAME:026978/0392 |